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Abstract 
Background 
Does promoting patient activation improve outcomes? We tested the hypothesis that 
provision of structured and personalised information can activate patients, promote self-
care, and improve outcomes. 
Methods 
We recruited all eligible people with diabetes in Wolverhampton CCG (n= 14,559), 
randomizing them into two groups. The active group was mailed their “My diabetes, My 
information, My plan” report at baseline, 3 and 6 months; the control group received 
standard care for first 3 months, then a single mailing. We compared a Failed Process Score 
(FPS = completion of nine processes; zero = full attainment) and HbA1c. A patient feedback 
survey was sent to 1000 randomly selected patients from the active cohort to assess the 
qualitative impact of this individualised report. 
Results 
At three months, the FPS score (1.25 ± 1.87 vs. 1.35 ± 1.97, P < 0.01) and the change in FPS 
score (0.48 ± 1.55 vs. 0.42 ± 1.49, P < 0.02) were significantly better in the active group. At 
12 months FPS score between group differences just failed overall significance (F=3.459, 
p=0.06).   However, in those with lower baseline activation (FPS of ≥2), FPS was significantly 
better (F=4.369, p=0.037, 3 month (p<0.01), 12 month (p=0.01)) in the multi mailed and 
their likelihood of achieving the good attainment category (12 month FPS ≤1) with mailing 
was 1.15 (95% CI 1.02 – 1.29, p=0.022).  Considering baseline HbA1c% categories as ≤7.5, 
7.6-8.4 and ≥8.5, and adjusting for variables in univariate analysis (r2=0.39, p<0.001; age 
p<0.001, gender (ns), ethnicity (ns), IMD score (ns), type of diabetes (ns)), the impact of 
being mailed multiple times was significant (F= 6.2, p=0.013).In the patient feedback survey, 
patients found this report useful (89%), a source of knowledge (78%) and confidence (74%) 
and it helped them in understanding their diabetes (78%). 
 
 
 
15 
 
Conclusion 
The provision of structured and individualized information to people with diabetes can 
positively influence the level of patient activation, promote better engagement and open 
the potential to improve other crucial diabetes outcomes. 
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Chapter 1: Introduction 
Diabetes 
Diabetes is a common chronic disease that is described as a metabolic abnormality of 
carbohydrate, fat and protein metabolism resulting in high blood sugar levels due to total or 
relevant insulin deficiency (1). Insulin is a hormone that is produced by pancreatic beta cells 
in response to carbohydrate and protein in ingested food (2). Hyperglycaemia in turn causes 
long term micro and macro vascular complications affecting multiple organs in the body (3). 
Diabetes is widely divided into Type 1 and Type 2 diabetes. Other common types include 
gestational diabetes and terms like impaired fasting glycaemia and impaired glucose 
tolerance are used to describe early abnormalities in carbohydrate metabolism (1). Other 
rare form of diabetes include genetic defect in beta cell function, genetic defect in insulin 
action, disease of exocrine pancreas, endocrinopathies, drug or chemical induced, infections 
and idiopathic diabetes (4). Diagnosis is made on the basis of presenting symptoms and 
fasting blood tests, according to the World Health Organisation (WHO) criteria (5).  There 
are different treatment options available based on type of diabetes, severity of disease at 
presentation, complications and other patient related factors that dictate the best suitable 
treatment option for the individual with diabetes. Over the last 15 years, diabetes treatment 
has progressed rapidly to provide multiple drug modalities to treat this disease. In the 
United Kingdom, the National Institute of Clinical Excellence (NICE) produces guidelines for 
treatment of diabetes and its complications through a continuous process of evaluation of 
the latest evidence around drug treatments and best practice across the world (6-8). It 
guides clinicians to perform at a set standard to facilitate the uniformity of care across the 
country.   
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Complications of Diabetes 
Complications in diabetes are multifactorial, most importantly hyperglycaemia induced 
advanced glycation end products that trigger multiple enzymatic and non-enzymatic 
pathways resulting in tissue specific secondary responses (9). This results in micro and 
macro vascular end organ damage resulting in retinopathy, neuropathy, nephropathy, 
possible secondary cardiovascular disease and peripheral vascular disease (Fig 1.1) (10).  
This results in blindness, amputations, renal failure, myocardial infarction and 
cerebrovascular accidents leading to significant mortality and morbidity (11) as well as huge 
social and financial implications to the health economy (12).  It is now well established that 
if we treat diabetes early and effectively, these complications can be delayed or avoided 
(13). 
Fig. 1.1: HbA1C level and risk of micro vascular complications 
 
Adapted from DCCT, Diabetes 1995; 44:968-43  
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Treatment options for Diabetes 
Treatment for diabetes was revolutionised through the discovery of Insulin in 1921 (14). 
Early oral hypoglycaemic agents like Sulphonylureas and Biguanides were the mainstay of 
oral treatment of diabetes until the last decade of 20th century. Since then there has been 
an explosion of new treatment options made available to people with diabetes, namely 
Glitazones, Gliptins, GLP-1 agonists and SGLT2 inhibitors, and many more are in the pipeline. 
A variety of treatment regimen have been trialled and tested and overall, diabetes 
treatment has been completely revolutionized in the last 20 years. In the United Kingdom, 
the National Institute of Clinical Excellence (NICE) produces evidence based best practice 
guidelines to ensure uniformity of diabetes care. However, despite standardised guidelines, 
the diabetes treatment optimisation remains suboptimal and patchy across the country. 
This may be due to the fact that diabetes, like any other chronic condition, requires an 
integrated care delivery needing individualised and tailored treatment to suit the needs of 
every individual patient, rather than adapting to a standard guideline. This integration needs 
to be patient facing, robust, governed and flexible to accommodate the variety of needs of 
people to enhance compliance and concordance with the treatment to optimise medical 
management of the disease. 
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Diabetes Epidemic 
Diabetes is a silent epidemic that has slowly risen in prevalence from 2% in 1970 to 3.5% in 
1990 (15). Since then there has been a steep rise in diabetes worldwide rising from 4% in 
1995 (16) to 9% in 2014 among people aged over 18 years (Fig 1.2) (17). This is projected to 
affect 439 million adults worldwide by 2030. Between 2010 and 2030, there will be an 
estimated 69% increase in the numbers of adults with diabetes in developing countries and 
a 20% increase in developed countries (18). Diabetes has resulted in 1.5 million deaths 
worldwide in 2012 (19). It is estimated that diabetes will be the 7th leading cause of death 
worldwide by 2030 (20). 
 
Fig. 1.2: Worldwide Diabetes Prevalence  
 
Used with permission IDF Diabetes Atlas Sixth Edition, 2014 update.   
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State of the Nation 
In the UK, Diabetes prevalence has shown a steady rise from 2.8 in 1996 (21) to nearly 6% in 
2014. An estimated 9.6 million people in England are at high risk of developing diabetes (22) 
and a predicted 4 million people in England will have Diabetes by 2025 (23). This disease 
causes around 20,000 early deaths/year, 100 amputations/week (24), a leading cause of 
preventable sight loss in working age group and is a major cause of renal failure, ischemic 
heart disease and strokes (Fig 1.3) (25). It costs the NHS £10 billion per year, which equates 
to 10% of the total NHS budget and about 80% of that is spent on complications (26), most 
of which can be prevented by timely and appropriate interventions. The total direct and 
indirect cost associated with diabetes in the UK is currently estimated at 23.7 billion and this 
figure is predicted to rise to 39.8 billion by 2035 (27). Many people with diabetes across UK 
are not receiving standard diabetes care, reflected by huge geographical variations among 
different Clinical Commissioning Group (CCG) areas (28). Despite National Service 
Framework (NSF) for diabetes and Quality Outcomes Framework (QOF) in primary care this 
variation is disappointing. There are multiple factors identified for these variations but 
despite all conventional frameworks to improve care we have not yet achieved desired 
outcomes in diabetes care delivery. This reflects on the gravity of situation and necessitates 
the exploration of new ways to resource effective delivery of diabetes care at the highest 
standard. The present project is around the development of a new model of diabetes care 
delivery that addresses the needs of people with diabetes in a resource constrained NHS. 
There is a huge gap in evidence base around diabetes care delivery in the UK, and my aim is 
to test parts of my model in a robust research framework to provide high quality evidence in 
this difficult arena. 
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Fig. 1.3: Prevalence of Diabetes compared with prevalence of Cancer, Coronary Heart 
Disease and Stroke by Year 
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Diabetes Care Delivery in 20th century in the United Kingdom 
It is clear that a disease of this scale need to be dealt with by exercising great caution and a 
robust strategy is required to deliver care to people who suffer from this illness. It requires a 
framework of care delivery that is structured, efficient, governed, needs driven and able to 
cope with the rising demand of the disease burden. In order to understand modern diabetes 
care delivery in the UK, it is important to understand the evolution of diabetes care since 
the discovery of insulin. 
Historically, with the advent of insulin in 1921 (14), diabetes became a specialist disease 
that requires specific skills. Initially, diabetes care delivery was restricted to specialist 
hospital clinics that were solely responsible for the diagnosis, management, patient 
education, record keeping, follow up and complication management. The first Diabetes 
centre in the UK was established in 1923 at King’s college hospital and this progressed to a 
network of diabetes clinics across England and Wales by 1950. After coping with the disease 
burden for nearly 3 decades, the capacity of the hospital clinics was overloaded by the rising 
number and needs of people with diabetes. This correlated with a steady rise in diabetes 
prevalence and increasing awareness of the disease and its complications. It further resulted 
in overcrowded diabetes clinics with increasing patient’s dissatisfaction.   
In 1953, the capacity issue was addressed through a trial involving trained health visitors in 
diabetes care. Their role was to liaise with specialist clinics, general practitioners and public 
health departments in order to provide patient education and monitor the treatment in 
newly diagnosed people with diabetes (29). This was perhaps the start of community and 
domiciliary diabetes care. The role of these health visitors, considering them being first step 
in the evolution of diabetes specialist nurses, varied widely from monitoring people who are 
newly diagnosed with diabetes, during inter-current illnesses,  pre-gangrenous foot 
infections as well as looking after hypoglycaemia and injection sites monitoring. Their scope 
was further extended to children with diabetes to liaise among their homes, school, family 
practitioners and specialist diabetes clinics. Although a very useful addition to the 
workforce, there was still a major gap in care delivery outside specialised hospital clinics.  
Like any other chronic diseases, people with diabetes require on-going help on a routine 
basis. A steady rise in the prevalence of diabetes made it obvious that no specialised clinic in 
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the world can provide care to the number of people being diagnosed with this disease. Until 
this time diabetes care was relatively unstructured and different clinicians had different 
treatment targets and thresholds for the management of disease and its complications (30). 
Overall this resulted in increasing clinician’s dissatisfaction as workload in clinics were 
becoming unmanageable and standards of care were more routine rather than expert 
reviews (31). 
To overcome this growing problem, the role of general practitioners was deemed 
paramount. Malins wrote that "most physicians who run diabetic clinics would be glad to 
know of any satisfactory method by which patients could be returned to the care of their 
own doctors" (31). There were several factors that undermined the role of general 
practitioners in the management of uncomplicated diabetes. One reason was the availability 
of diabetes clinics in most areas where such clinics were by default considered responsible 
for the delivery of care to the local population. Another reason was that GPs trained before 
the advent of these diabetes clinics had learned little about management of this condition 
and were not very skilled or confident in taking over the responsibility. Last but not the least 
was the maintenance of competencies, because on a standard GP list, there will be only 8-
10 people with diabetes that make it difficult for GPs to acquire and retain skills (32). 
 There were three possible ways in which the role of GPs could be explored to include them 
as effective partners in the care delivery of diabetes. One approach was to support GPs by 
providing them with a structure of care and encourage them to set aside one full clinic once 
or twice a month dedicated for diabetes reviews. The main emphasis was that the GPs will 
need a structure of care to follow with the help and support of their local diabetes clinics 
until the level when they achieved competencies to manage uncomplicated diabetes by 
themselves. This concept of structured diabetes clinics was rolled out in Wolverhampton in 
1970 by Pat Thorne, and known as the Mini-clinics in General Practice (33).  Every new 
patient regardless of their type of diabetes that was once seen by the specialist hospital 
clinic and deemed suitable to be looked after in primary care was discharged back to his or 
her GP with a management plan. This was followed up by structured input from specialists 
in the form of a management plan that navigated a treatment strategy to the GPs to define 
the most likely course of disease in next 6-12 months and how to manage it in the 
 
25 
 
community. If required, the person could be referred back to the hospital at any given point 
for further advice on management and to review the plan. GP practices choose to dedicate 
one clinician to develop an interest in looking after people with diabetes. They were 
supported by the hospital specialists in variety of ways including case based discussion 
sessions, informal and formal remote patient enquiries as well as by offering them to sit in 
diabetes clinics with specialist to acquire more knowledge and skills to manage complexities 
of diabetes. An annual visit to the surgeries by specialists was also arranged and was found 
to be very welcoming. All this was underpinned by the principles of co-working of clinicians 
and a uniform structure to deliver care to people with diabetes. As these clinics were 
running successfully, the need for motivation and enthusiasm of clinicians and structural 
organisation and governance in standardised care delivery of diabetes was considered to be 
of utmost importance (34). A 10 year audit of Mini-Clinics showed that there was no 
significant difference in diabetes control between people who were under specialist care, as 
compared with those who were looked after by their GPs in structured and well organised 
primary care clinics (35). This was a retrospective audit to assess service delivery that was 
not rolled out in a research framework, and there could be many confounding factors and 
bias, especially enthusiasm of the clinicians involved in Mini-clinics, that can make a huge 
difference in the outcomes of such initiatives. There can also be a selection bias, as despite 
matching the demographic details of the patient, the extent of disease and its complications 
managed in hospital clinic versus Mini clinics can make this judgment difficult. Despite this 
weakness, this was the first evidence available to compare the outcomes of people with 
diabetes under the community diabetes care against hospital clinics, and the results were 
very re-assuring. This idea of mini clinics was implemented at other sites in the UK and 
produced similar outcomes (36). 
Another strategy was to explore the potential of active involvement of GPs in diabetes care 
delivery in shared care settings. A community diabetes service was set up by involving GPs 
to work in close collaboration with hospital clinics. An agreed education programme was 
launched to keep GPs up to date with advances in diabetes treatment. Hospital laboratory 
access was extended to GPs to facilitate 2 hours blood sugar monitoring tests in order to 
evaluate their patients in the community. An effective way of communicating between 
hospital and GP surgeries was established to seek support and ensure patient safety (37). 
 
26 
 
The outcomes of this whole process were assessed from patients’, GPs’ and the hospital’s 
viewpoints. It was found that people liked to be looked after by their own GP due to more 
personalised care, less waiting time and continuity of care delivered to people who are 
essentially have no complex care needs. This has eased off the burden on the diabetes 
clinics, which can concentrate more on complex care needs of people who have 
uncontrolled or complicated diabetes. Although initially, GPs felt an increased workload in 
their day to day practice, many were keen to continue to provide care to their patient and 
found it challenging but rewarding (37). This is again a service development and shows 
mainly soft outcomes based on questionnaires to assess impact of this new service provision 
on the patients, their GPs and specialists. There was neither a control group, nor any before 
and after comparison on hard outcomes such as blood sugar control. However, one should 
not undermine the positive impact of perception of co-working in a patient centric way that 
emerged from this service development. Key outstanding questions from this shared care 
strategy were whether this strategy will continue to provide favourable results in the long 
term, how much care should be shared, and to what extent real sharing will take place. The 
economic evaluation of such strategy was required to assess the cost effectiveness of this 
approach. 
Another strategy was to ask GPs to take responsibility for the care of their patients without 
any structure of support in place. This means that individual GPs have to assess their own 
needs for knowledge, skills and support to ensure adequate delivery of care to people with 
diabetes registered in their practice. People can be arbitrarily discharged from specialist 
care to their GP care without any close communication or any agreement with their GPs. 
This was subject to a 5 year follow up randomised control trial to compare primary care 
outcomes against specialised hospital clinics. Unsurprisingly, the results were found to be in 
favour of specialist care, and people under the so called “routine GP care” showed 
worsening glycaemic control and higher complication rates (38). This was a single centred 
trial with a relatively small sample size, and most of the confounding factors were related to 
lack of organisational governance, rather than the ability of the clinician to manage 
diabetes. For example, a major constraint was the lack of facilities and resources available to 
GPs to effectively deliver diabetes care in their practices. These included the non-availability 
of dietary advice, podiatry and access to lab services to monitor blood glucose. This trial 
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may have been designed to assess the specialism of generalists against the specialists of a 
disease and hence outcomes should not be surprising. The authors acknowledged that in 
other areas where mini-clinics or shared care proved to be successful there was significant 
organisation around these clinics in primary care. No similar trial was conducted either at 
the same place or within a different health economy to validate these findings and to 
address issues around possible bias of lack of facilities in this particular area against the 
clinician’s ability to manage diabetes. This trial posed a great challenge to primary care 
physicians who were seeking to establish their role in long-term care delivery of diabetes. 
Hence by comparing these three strategies over a period of about 2 decades it was clear 
that in order to cope with increasing workload of management of diabetes, primary care 
had to play an important role. Although motivation and enthusiasm of GPs played an 
important role in care delivery of diabetes it required a structural, organisational, 
educational and clinical governance frameworks to enhance the efficiency of the system and 
to achieve comparable outcomes of disease regardless of its place and mode of delivery 
(34). Several factors such as care being closer to home, more personalised care, holistic 
approach to deal with multi morbidity, continuity of care and its ability to influence lifestyle 
modifications made a strong case for the involvement of primary car in long term condition 
management, such as diabetes.  
One of the important care processes in routine diabetes care that primary care was unable 
to deliver in the community was the detection of retinopathy. The role of ophthalmic 
opticians in screening for diabetes retinopathy, as well as diagnosing people with diabetes, 
was well recognised by the mid 1980s (39). The importance of retinal screening was further 
evaluated by Buxton et al, who compare different methods of screening by primary care, 
specialist clinics and ophthalmic opticians (40). It was obvious that this particular care 
process require a specialised retinal screening service regardless of place of care delivery. 
Therefore, in order to deliver structured diabetes care, the availability of specialised 
resources like retinal screening and perhaps podiatry and dietetic has to be shared between 
primary and specialist care. As the rest of routine diabetes service was deliverable in 
primary care, clinicians have shown both intent and commitment to acquire knowledge by 
engaging with educational programmes (41) and to take responsibility for their patients.       
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Nonetheless, delivering structured care in general practice led to a debate on how much 
specialisation is required in primary care, and where the boundary of care delivery should lie 
between primary and specialist care. On the question of specialisation, there were two 
schools of thoughts. One was in favour of one person in a practice acquiring knowledge and 
skills to deliver diabetes care. This latter concept evolved in the idea of GP with special 
interest (GPwSI). The benefits of this were higher skill level, continuity of care and facilitated 
primary and specialist care communication with one nominated person. Another school of 
thought was in favour of up skilling whole primary care, so that each individual GP should be 
able to provide standard diabetes care to whole population. The benefit of this approach is 
to expand your work force significantly, as well as holistic care delivery to all people at a set 
standard. The overlap of care between primary and specialist care services can be variable, 
and its existence in different shapes and forms like shared care, mini clinics and sole GP care 
has already been discussed. At the beginning of 1990, the new GP contract urged general 
practitioners to take more responsibility for looking after people with diabetes, and 
although the confidence to manage diabetes as well as other services like dietetic and 
podiatry were inadequate, there was significant interest and enthusiasm expressed by the 
GPs in taking diabetes care to primary care settings (42).     
Diabetes care delivery in shared care or primary care settings in the 1990s was extensively 
reviewed, first by Greenhalgh (43) and then by Griffin (5). The most important findings 
demonstrated that effective, efficient and safe diabetes care to people with diabetes can be 
delivered regardless of the geography of primary and specialist services by extensive 
planning that assesses the best way to deliver care according to local needs and in 
consensus with primary and specialist services. This delivery is also enabled by written and 
agreed guidelines or care pathways, a systematic call recall system, involvement of 
motivated GPs with interest in diabetes, supported by enthusiastic specialist liaise on team, 
effective outreach team led by a specialist nurse to provide support to primary care, and by 
risk stratifying people with diabetes to transfer them to primary or specialist care in a rolling 
framework of audit and outcomes assessment.  
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Patient Education 
Despite this evolution and the improvement in the medical management of diabetes in the 
last century the overall quality of diabetes care remain suboptimal. Like any other chronic 
disease, a large proportion of diabetes management has to be carried out by the person 
with the disease. Poor understanding of this concept of patient participation in their own 
care, for which they need to be educated to take control of several aspects of their disease, 
was one of the key reasons for the failure to improve diabetes care.  Although there was a 
very early recognition of the importance of patient education by pioneers of diabetes like 
E.P Joslin who created a diabetes teaching clinic in Boston in 1929 and  R.D Lawrence who 
founded the British Diabetes Association in 1934, the benefits of patient education took 
nearly 5 decades to get acknowledged and understood. To understand the importance of 
this highly important, yet very simple aspect of care, we need to look at the variety of issues 
related to the metabolic manifestations of diabetes. It swings from the extremes of 
glycaemia; severe hypoglycaemia to hyperglycaemic states like diabetic ketoacidosis; from 
mild numbness in the limbs to the total loss of sensation with the serious risks of foot ulcers; 
from mild visual symptoms to complete blindness; from minor circulation issues to gangrene 
and amputation and from likely reversible micro-albuminurea to end stage renal failure. 
Other key aspects that play a significant role in the metabolic control of this disease include 
patient’s nutritional status, lifestyle habits, psychological constitution, familial, professional 
and social factors to name but a few.      
This complex spectrum of acute and chronic complications of the disease requires the 
education and training of patients to cope with the daily individualised demands of the 
disease burden. If we review the history of patient education in clinical practice, one of the 
earliest contributions was by E.P Joslin in the form of a book called “A Diabetic Manual” 
published in 1919 (44). This book was written for clinicians to guide them on how to educate 
their patients to deal with diabetes. With the discovery of Insulin, and after early failures of 
treatment of some of his patients on insulin, Joslin stated that “it is a waste of time and 
money unless the patient was thoroughly instructed to manage his own case” (45). In order 
to implement this concept of patient education and training, in the 1920s he introduced the 
concept of a diabetes nurse educator and diabetes wandering nurse to deliver diabetes 
education programme in the hospital and community respectively (46).  
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In the meantime, in 1941, R.D Lawrence edited a manual entitled “The Diabetic Life: Its 
Control by Diet and Insulin. A Concise Practical Manual for Practitioners and Patients”(47). 
In its introduction, he wrote “it is the object of this book to bring modern treatment of 
diabetes by diet and insulin within the scope of general practitioner and the understanding 
of patients whose intelligent co-operation is necessary for the best results”. This manual 
essentially laid down the foundations of patient education and training as an active 
participant in their own care to achieve success in medical treatment. However it is very 
surprising that despite this excellent initial work, this idea was not widely accepted among 
the healthcare professional’s community of diabetes in the UK up until the 1970s. Increasing 
evidence in favour of patient education and its relation to better outcomes by the work of 
Miller (48), Davidson (49) and Moffitt (50) in the late 70s looking at reduction in acute 
hospital admissions, cost effectiveness, bed occupancy and improved outpatient outcomes 
attracted the attention of the world to understand and accept the importance of the 
diabetes teaching programmes in reducing metabolic variability and improving short and 
long term clinical outcomes. Thereafter, there was a wider acknowledgment of this highly 
important aspect of care, and the American Diabetes Association and the European 
Association rolled out two huge initiatives in the form of setting up of American Association 
of Diabetes Educators and the Diabetes Education Study Group (DESG) respectively in 1979. 
This group produced a Europe wide report to identify confounding factors in implementing 
patient education in daily clinical practice. Key factors were a) poor patient motivation, b) 
lack of specific training for patient education, c) organisational difficulties to integrate 
patient education in routine diabetes care, d) lack of data and methodologies to assess 
effectiveness of such programmes (51).  The suggestions were implemented across the 
Europe during 80s by organising 100 workshops to raise awareness and provide training, 
attended by around 1000 doctors and 1000 nurses. A huge impact was created by a series of 
teaching letters on about 20 different topics of interest in 25 different languages (52). Since 
then, diabetes education started to become an integral part of the care delivery of diabetes. 
Various different methods including individual and group teaching, as well as innovative 
educational tools like computer based programmes (53),(54), were introduced in the last 
decade of 20th century. An increasing awareness of people and growing will to gain as much 
independence as possible motivated people to take up such programmes and maximise 
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their benefits. Increasing acceptance by healthcare professionals also played a key role in 
integrating patient education in routine diabetes care delivery. At the end of the last 
century most interventions to improve the diabetes care tried in primary care, outpatient 
and community settings showed that patient education, effective call and recall system, 
exchange of patient information among healthcare professionals and use of 
multidisciplinary team in the community can be beneficial to various patient related 
outcomes (55).  Overall the landscape of the NHS diabetes care delivery changed when 
Primary care took on increasing responsibilities for the care of their patients and GPs were 
willing to improve their skills and expertise in chronic disease management in the 
community (56).    
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Diabetes Care Delivery in 21st Century 
At the beginning of this century, it was generally understood that care for people with 
diabetes was challenging, and by examining the evolutionary process of care delivery, it 
seems clear that in order to meet the needs of people with diabetes, both primary and 
specialist care had to play a vital role and needed to work in collaboration with each other. 
It was also well recognised by that time that patient education and involvement in their own 
care had a pivotal role to achieve desired short and long term clinical outcomes. As diabetes 
care expanded from the hospital to primary care to the community there was a need to 
ensure that a standardised service be provided to all people regardless of their portal of 
care delivery. This led to the introduction of the National Service Framework (NSF) for 
Diabetes in 2001. This document delineated 12 set standards to deliver a high quality 
diabetes care to children, young people and adults across the bounds of the NHS (57). NSF 
set standards of care around prevention, early diagnosis, people empowerment and shared 
decision making to facilitate self-management, optimisation of clinical management, clinical 
care of children and young people with diabetes, management of diabetic emergencies, 
hospital admission and stay, pregnancy in diabetes and detection and management of long 
term complications. After the initial reluctance to accept NSF by the primary care (58), it 
was found to be of great value in achieving the required standards of care with the 
introduction of financially incentivised Quality and Outcomes Framework (QOF) for primary 
care, launched in 2004 with the new primary care contract (59). Practices were provided 
with an opportunity to receive financial rewards to deliver quality care at a very high 
standard. In the QOF that was initially launched for 12 chronic diseases including diabetes, 
most clinical quality indicators were derived directly from NSF for diabetes. Organisation 
standards such as keeping a register for all people with diabetes and maintaining their 
record and medicine management further enhanced the ability to evaluate the standard of 
care that was delivered by the primary care to their patients.  Patient experience and 
additional services were also incorporated in QOF to facilitate good quality care delivery to 
people’s satisfaction. After embedding QOF as an integral part of primary care delivery in 
the UK for few years it was evaluated and showed an improvement in quality of care in 
terms of process completion as well as clinical outcomes (60). This was a systematic review 
that found 5 suitable comparator studies against QOF. All these studies were cross sectional 
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surveys, and demonstrated that financial incentive scheme of QOF has shown improvement 
in documentation and recording of diabetes care processes and although an improvement 
in intermediate outcomes is seen, long term morbidity and mortality outcomes were yet to 
be established.  The limitations of QOF in delivering care to less organised practices and 
deprived areas (61), as well as meeting needs of specific group of people for example people 
with Type 1 diabetes and people with very poor glycaemic control (62), were observed in  a 
retrospective cohort study. All this evidence suggests that there is a need to pursue the 
agenda of structured diabetes care in a standardised framework of practice in the UK to 
minimize geographical and other relevant variations in delivery of care by setting up 
minimum standards to meet the desired care delivery to all people with diabetes. 
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Models of Diabetes Care delivery 
It is evident that any model of diabetes care delivery in 21st century that caries the notion of 
“Integrated Care” may be based on the fundamental principles of care delivery derived by 
the remarkable work done in the latter half of the last century as discussed above. Modern 
concepts of integrated care delivery models can be traced back to the concepts of mini 
clinics, shared care and co-working of primary and specialist care clinicians, as well as 
fundamental principles of patient education, empowerment and shared decision making. 
For any model of care delivery to be rigorous and sustainable, it should incorporate 5 
fundamental pillars of governance that include clinical, structural, organisational, financial 
and data governance. The development of a district wide diabetes service in North Tyneside 
between 1979 and 1991 provided a detailed understanding of the evolution of such a model 
of diabetes care delivery that uses the principles of structured approach, patient 
empowerment, integration of care, performance management and team work to build a 
district wide diabetes service (63). This concept of multifaceted approach was further 
developed in the chronic care model (64) and was the foundation for the new house of care 
model for people living with long term conditions such as diabetes (65). This model evolved 
over years into its practical form in the “Year of Care” project. In this pilot project, which 
took place at three distinct sites in the UK, the importance of information provision to the 
service users to inform care planning process was assessed and found to be of benefit (66).  
In the 21st century, the importance of patient engagement has been explored under 
different notions of enablement, empowerment, self-care, partnership working and patient 
activation. It is increasingly acknowledged that without promoting people to self-care for 
their diabetes, it can be difficult to achieve outcomes. In an extensive multicentre cross 
national study to examine psychological problems and barriers to improved diabetes 
management, it was found that the psychological wellbeing of the patients plays an 
important part to promote self-care and without understanding people’s attitudes, needs 
and wishes, the achievement of optimal glycaemic control may not be easy to achieve (67). 
This was a large scale, multi methodology and diverse study, but has the potential bias to 
include better educated people, due to the study design and type of interviews used in the 
study. There can potentially be cultural and resource bias in the study, due to the 
involvement of multiple countries of varied sociocultural dynamics.  
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Different models of care have been trialled in the last 15 years in the UK. All of these models 
have used one or the other fundamental principles of chronic disease care delivery. Some of 
the models use categorical classifications to decide whether people are suitable to be 
looked after by the primary or specialist care teams. The Super Six model of Portsmouth (68) 
is a representative example of this approach, and has shown some benefits in terms of cost 
savings and increased patient satisfaction after 2 years (69). The outcomes reported from 
this initiative need to be looked at with caution as there is no control group to assess the 
impact of this new approach, and outcomes are based on a before and after analysis of 
multiple endpoints that are used as a marker of improved service delivery and better 
disease related soft outcomes without looking at defined hard endpoint clinical outcomes. 
One possible downside of such an approach is that it can demarcate the bounds of primary 
and specialist care based on the defined category, rather than needs of individual patient 
and referral across the categories will be clinician rather than need dependent. It can easily 
overlook complex cases of type 2 diabetes that may require highly specialised care, in order 
to prevent or halt complications. Leicester primary care also has a similar approach, 
although they have added an additional category of “people with complex needs” (“Super 
Seven”) to address this issue. 
A tiered system of care has also been reported in several places across the country. One way 
of developing a tiered approach is to develop an intermediate service run by the GP with 
special interest and takes the initial referral from the primary care and then to escalate it to 
specialist care as required. There is little published evidence available of such an approach 
in the form of an RCT to assess the effectiveness of this approach and results have shown no 
benefit when compared against the standard practice of direct referral to specialist care 
(70). This study used a cluster-randomised design, and only included people with type 2 
diabetes. This is appropriate as most type 1 diabetes is already under specialist care. It was 
found that there was a slight improvement in HbA1C and cholesterol control, but less so in 
blood pressure in people looked after by intermediate care, although it was statistically non-
significant. However, the role of intermediate care in patient education and improving skills 
among primary care might be more relevant than achieving hard clinical outcomes. This trial 
provided a valuable insight into the difficulties faced to conduct a real life, innovative, 
pragmatic and cluster randomised trial due to less than expected recruitment in the trial 
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and high numbers of loss to follow up.   Another example of a tiered approach by up skilling 
of group of practices rather than individual GPs was tested in Blackpool, and although it 
showed some benefits, this model was decommissioned by the local clinical commissioning 
group after a short while and hence has not produced any quantifiable published outcomes.  
Out of hospital specialist care by collaborative work of primary and specialist care clinicians 
as a subcontractor of the NHS within the framework of an independent organisation (private 
company) has been implemented in Derby (71). It constitutes 50% participation of primary 
and specialist care, integrated IT system and single budget to deliver outcomes. It has 
shown significant outcomes in terms of better glycaemic control, reduction in weight and 
insulin dose and cost effectiveness. These outcomes are not compared against a control 
group and some of them are based on before and after intervention analysis. This model is 
also in a sustainability crisis at present as this could be seen as duplication of those services 
by a third party provider that has already been commissioned to be delivered by the 
standard NHS organisations. 
Another model of integrated care based on multi-agency collaboration is the Northwest 
London Integrated Care Project (ICP), which looks after people over 75 years or people with 
diabetes. It has multiple interventions, including an outpatient triage service as well as a 
facilitated discharge service to provide rehabilitation in the community. Early projected 
outcomes in terms of hospital admissions, bed days, cost savings and user satisfaction still 
need to be backed up by the real outcome data (72). 
Information Technology is required to play a key role in the integration of services and the 
effectiveness of this tool has been valued in First Diabetes model of Derby (71) as well as 
Bradford diabetes services. By having a shared database between primary and specialist 
care, a whole new world of virtual integration can be explored with the potential for cost 
savings as well as providing a risk driven service without actual patient movement achieved 
by virtual consultations and sharing of expertise among clinicians (73). 
The co-working of primary and specialist clinicians in the community can easily be confused 
with the term community diabetes. This term is often used for the provision of care by a 
specialist outside the hospital at a different site, most often in a GP surgery. Community 
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diabetes remained a great area of interest in the last 15 years but in author’s view, 
geography does not define the mode of care delivery to people. A specialist doing a clinic 
outside the hospital should not be taken as any different than doing a clinic in the hospital. 
Therefore, rather than dividing the care into community and hospital diabetes, care should 
be need driven and risk stratified regardless of its location, going back to the ethical 
principle of right care at right time by the right people (74). However, different co-working 
strategies have been tested, and one recent example is the Wakefield model of care. This is 
based on the principle of shared care, and is executed by specialists visiting the primary care 
physicians on a regular basis in order to address needs of people without necessarily 
referring them across the boundaries of the NHS (75). A similar integrated co-working model 
in community setting has been tested in Bolton and has shown a significant reduction in the 
number of hospital bed days per person (76) .This is a similar approach to that was used by 
P Thorn in his idea of mini clinics, where GP will be visited once a year by a specialist 
colleague to develop a mutual working relationship (33). Despite all these evolutionary 
changes spanning over a period of 7 decades, the fundamental question remains as to 
whether the NHS has developed a model of care delivery that has a firm evidence base in 
regards to its effectiveness, that fulfils the needs of people and is adaptable to the wider 
NHS to provide universal and standardised care.  
Outside the UK diabetes care varies widely depending on the nature of the healthcare 
delivery system. Most of the world runs on insurance-based health services with priorities 
being dictated by a balance between ethical principles and financial incentives. It is a hard 
balance to maintain, but there are quite a few examples where health care delivery is 
guided by similar fundamental principles to those of the NHS. Two of these examples that 
are widely studied by the NHS are United States based Health Maintenance Organisations 
(HMO) called Kaiser Permanente (KP) and Medicare. KP, mainly based in California, serves 
both insurer and provider arms of the healthcare and hence has close resemblance to the 
modern NHS. It was found that both of these organisations has a better outcome data for 
their numbers of hospital admissions as well as length of stay in most chronic diseases 
including diabetes when compared against NHS (77) and although this report was criticised 
for not presenting the evidence to support that Kaiser's better bed utilisation is due to 
integration of care, active management, use of intermediate and self-care, and leadership 
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(78). It was also found in a randomised controlled trial within KP that one reason for 
reduced bed utilisation in diabetes was the introduction of a multidisciplinary integrated 
outpatient diabetes care management programme in the community that led to better 
integration across primary and specialist services (79). This trial excluded people over the 
age of 75 and those with well controlled diabetes, leading to potential selection bias. In this 
context, it is understandable that a significant improvement in glycaemic control was 
observed in this trial over a relatively short period of time.  The question of whether the 
NHS can learn from KP was answered by suggesting that there is a huge potential in the NHS 
to implement a change of focus by promoting integration and ownership. This can be 
achieved by aligning the goals of clinical and managerial staffs, implementing risk 
stratification, case finding and management, encouraging accountability by peer review in 
order to manage standard of care, and more financial incentives to deliver high quality care 
by perhaps agreeing on standards at more local level rather than generalised 
implementation of agenda of care across the NHS (80). A summary of the evolution of 
diabetes care delivery in the UK is shown in Fig 1.4. 
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Fig. 1.4: The Evolution of Diabetes Care Delivery in UK-Past, Present and Future   
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Integration of Care 
At present there is a huge drive in the NHS to move towards the notion of integrated care. 
This notion has several perspectives, and can be understood as an approach to improve the 
quality of care to the service users by collaboration of services to achieve a common goal of 
meeting clients and their carers’ unmet and complex needs. The ageing population, increase 
in prevalence of chronic diseases and new and modern management options have made it 
increasingly difficult to provide high quality healthcare in a resource constrained NHS. In 
order to meet this challenge, the NHS has to change and adapt an innovative, efficient and 
effective approach to tackle issues like inefficiency, waste and poor productivity. The way 
forward is to provide integrated care according to the needs of people across system 
divides. Integration of care can be horizontal where all the services operating at one level 
and sometimes under one organisation work in collaboration, or vertical where services 
across different organisations or operating at different levels work together to provide all 
elements of care in a seamless continuum of care (81).  Integration can also be real when all 
the services are operated under the umbrella of one organisation, for which HMO in US like 
KP is a powerful example (82).It has been tested in the NHS as a model of care for older 
people in Torbay where both health and social services demonstrated the effectiveness of a 
real horizontal and vertical integration in providing care to people with complex needs (83).  
This Integration can be “virtual”, whereby multiple organisations can work together under 
an agreed framework of governance to provide multidisciplinary care to accommodate 
targeted population with complex needs that can be based on their multi morbidity but can 
also be based on individual parameters like age, or can be disease specific. One example of 
such integration is North West London ICP, where more than 100 general practices, 2 acute 
care trusts, 5 primary care trusts, 2 mental health care trusts, 3 community health trusts, 5 
local authorities, and 2 voluntary sector organizations join together to serve over half a 
million population who was either more than 75 years of age or has diabetes (72), (84).  
No matter what shape and form of integration is used, it needs to serve the purpose of 
delivering high value care in the context of increasing disease burden and difficult financial 
and organisational environment. Despite testing many model of care delivery no one model 
is found to be perfect, and there is an increasing understanding that organisational 
integration is neither necessary nor sufficient to deliver the benefits and it is clinical and 
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service level integration that is fundamental to produce desired outcomes (85).  In an 
increasingly fragmented NHS, there are several barriers to achieving this integration: an NHS 
management culture that is permission based and risk averse; increasing primary and 
secondary care divides in the form of contracts, funding approaches and different priorities 
of service provision; lack of time and resources to support integrated care to sustain (86) 
and lack of research methodology applied to such projects in order to come to a meaningful 
conclusion; too much focus on organisational performance in comparison with performance 
across organisations and around patients, inability to develop a common framework to 
promote joint accountability for delivering patient centric services (87) and the absence of 
robust shared electronic patient records are key issues that require urgent attention (85). 
Most recently, a comprehensive systematic review to assess the effectiveness of quality 
improvement strategies on the management of diabetes has been published (88). This 
review included strategies targeting healthcare systems, which include case finding and 
management, team changes, electronic patient registry, facilitated relay of information to 
the patients and continuous quality improvement (plan-do-study-act). Other strategies to 
target healthcare providers include audit and feedback, clinician education, clinician 
reminders and financial incentives and finally the strategies that target patients such as 
education of the patients, promotion of self-management and reminder system. All of these 
have been looked in both randomised and cluster randomised trial settings. The impact of 
these strategies was assessed not only on HbA1C but also on vascular risk profile. It was 
concluded that the strategies that have a pan system intervention strategies has a better 
impact on diabetes management and outcomes. Interventions that only target healthcare 
professionals are found to be significant only in those patients with poorer baseline Hba1C. 
The limitations of this study include varied baseline or standard care across various 
countries and selection bias of the trials published in English language only. Due to the large 
number of trials included there were inconsistencies in the defined outcomes of the trials 
hence made it difficult to assess the extent of secondary outcomes such as vascular risk and 
complications. Despite these weaknesses, the important message delivered in this trial is 
that non-pharmacological interventions can deliver both qualitative as well as quantitative 
benefits in clinical surrogate markers of diabetes. These benefits are modest with mean 
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HbA1C improvement of 0.3-0.4%, but they can be seen in the comparison of the benefit 
achieved by adding a 3rd line oral hypoglycaemic agent.    
Regarding delivery of an integrated care, a recent mixed method case study used 
hospitalisation of people with diabetes as an index to assess the effectiveness of the 
healthcare delivery system across the bounds of primary and specialist services (89). This 
study is based on a 3 year long pilot project using a before-after design with control from 
adjacent geographical areas. This study concluded that investment in a separate community 
diabetes specialist service has not shown any benefit in rate of hospitalisation, but has 
increased fragmentation between primary and secondary care. Lack of clinical, financial and 
data governance were found to be the key issues led to the failure of the effective delivery 
of care. This study had a weak design, and there was lack of availability of complete dataset 
that might have an impact on the overall conclusion but unlikely to have changed it 
significantly.   
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Vision for the Future 
The above discussion has highlighted the fact that diabetes care delivery is a complex 
subject. Over the course of more than half a century, remarkable improvements have been 
made in diabetes care delivery. We have moved from an era of unstructured, specialist led 
services to a structured, organised and system wide diabetes care. Despite several attempts 
to assess the effectiveness of various interventions the evidence in this arena is very limited. 
There is a need to explore various strategies by using the research with robust methodology 
to provide high quality evidence. The perception of the available evidence suggests that it is 
difficult to conduct research in this area, due to certain barriers such as multiple 
stakeholders’ involvement, lack of differentiation between a service development and a 
research project as it seems easier to implement such initiatives as a service development. 
This loses the benefit of the control group in the assessment of the impact of such 
initiatives. Therefore, many reported improvements in outcomes could be due to temporal 
changes or confounding variables. As these interventions so far have only shown modest 
improvements, and in presence of a positive publication bias, there is a lack of 
encouragement in conducting such studies. Although available evidence does provide a 
valuable insight into what should be an effective healthcare delivery strategy should look 
like, there is a need to explore whether a data driven, risk stratified, needs based approach 
to diabetes care will allow efficiency in care delivery in a resource challenged NHS. 
Based on this learning, there is a need to develop a model of diabetes care that should be 
based on the principles of corporate governance, should be ethical and principled, actively 
user centric and integrated at all levels of integration. It should address equality and equity 
in service access, process and outcome, be effective, efficient and appropriate by linkage to 
risk and modifiable risk. To deliver a resource efficient service in a finance restricted NHS we 
have to develop a model that can treat people according to their needs based on their risk 
profile. This means targeting people at higher risk with fully integrated services, while 
routine care is offered to those who are able to self-care even with little help and support. 
This type of focused care can only be developed if there is a risk stratification mechanism in 
place. Although in the past, risk based referral systems have been tested, above evidence 
suggests a suboptimal response to the needs of at risk group in a timely manner that can be 
influenced by the enthusiasm of clinicians involved in the care of the patient.  
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The introduction of QOF has facilitated data collection and electronic databases have 
become integral parts of all the services. QOF has shown great improvement in capturing 
the data around care processes and perhaps on intermediate outcomes but there is mixed 
evidence of any significant reduction in cost effectiveness, long-term morbidity and 
mortality (60, 90). Now there is an opportunity to use this available data to risk stratify the 
patient electronically based on their clinical parameters with less chances of getting lost in 
the system. This data can also be used to empower people by providing them with their 
personalised information in a structured format so that they can develop insight of their 
diabetes status and should be able to reflect how they can improve their care.    
WICKED (Wolverhampton Interface Care-Knowledge Empowered Diabetes) is an initiative to 
re-design local diabetes care delivery across the local health economy in Wolverhampton. 
This model has 2 core components; Patient Activation and Service Activation. The “Patient 
Activation” arm aims to empower the patient by providing them with their diabetes specific 
individualised information in a structured format regardless of the patient’s engagement 
with the service to promote self-care, and hence activate these patients in local diabetes 
care delivery. It is this arm of the model that has been tested in a cluster randomised control 
trial to assess the impact of this intervention of information provision to the completion of 
the nine key care processes in diabetes. In this trial, a structured A4 booklet containing 
individualised patient information is used as an intervention to encourage people to 
complete the key care processes that constitute standard diabetes care. The completion of 
the processes is the key element to inform local healthcare, and plays a vital role in risk 
stratification. This risk stratification strategy is the basis of “Service Activation” arm of the 
model that involves co-working between primary and specialist care around this cohort of 
people who are at higher risk of developing complications of diabetes. The whole model is 
thus based on the principle of equity in healthcare. In this model, all those people who can 
self-care can be managed without any pressing need to integrate resources around them 
but as the needs of the individuals increase, the model converge its resources to develop 
meso and micro integration among the services and people with diabetes to provide best 
possible care (Fig 1.5).  
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In order to execute such a project, there is a need to develop an understanding of the basic 
principles of the model as outlined above. A complete, live and validated database will serve 
as a core to the model and hence establishment and validation process of such a database 
will be crucial. To implement principle of equity in health care, it is important to develop an 
understanding around access to healthcare. A partnership working with activated patient 
will be key to success to develop a care plan and encourage patient to self-care therefore an 
attempt to test its implications in real life can provide a valuable insight. In the present 
thesis an attempt will be made to explore and develop an understanding around these 
principle areas of the WICKED model of diabetes care that include: 
• Establishment and validation of an electronic centralised diabetes register-its 
importance and utilization in delivery of health care. 
• Equity of access-understanding the barriers that affect Access to health care. 
• Partnership working-How the care planning can be facilitated by knowledge 
empowered people. 
• Impact of information provision to people with diabetes- Is it feasible? Will it be of 
any benefit? Can we find an evidence base? 
 Finally, the benefit of such integrated care delivery model should also show whether this 
has resulted in any improvements in outcomes. Such a system can then provide a toolkit for 
sustainability within the system as well as transportability to other regions.   
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Fig. 1.5: The WICKED escalator describing patient journey from uncomplicated low risk to 
complicated high risk diabetes. 
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Chapter 2: Establishment and validation of a 
centralised electronic diabetes register 
Background 
The burden of diabetes and related complications is increasing; the cost of newer 
medication is higher and the cost of high quality care is therefore increasing. Meanwhile, 
health care systems across the world are trying to cut costs, and providing high quality care 
at lower cost is not going to be easy in any health care systems. This requires innovative 
interventions to improve efficiency of the system and use of Information Technology (IT) 
can play a vital role in it. Electronic patient records have facilitated the use of data for 
various governance purposes, for example QOF and National Diabetes Audit. However this 
data has the potential to be used in more powerful way to drive direct clinical care of people 
with diabetes. 
 In order to provide care to people with chronic diseases, it is a basic requirement that 
health services should know about people who are suffering from the illness (91). In 
diabetes health delivery, hospital clinics have used several ways to keep a record of people 
attending the clinic. This was either in the form of hospital outpatient records or hospital 
diabetes register containing details of all people with diabetes attending the hospital. With a 
better understanding of long term but for some preventable complications of the disease 
there was an increasing need to ensure that people who are having complex needs should 
be able to attend the clinics as required. In order to keep a track of these people, a call recall 
mechanism was desired that could not have been delivered without keeping an accurate 
record of demographics of these people.  Due to the care division between primary and 
specialist care it was paramount to have a robust system of follow up in place with defined 
responsibilities of either service to ensure the arrangement of short or long term follow up 
(92). Keeping a practice register for all people who were discharged from the hospital and 
utilisation of very early punch card system was used both by primary and specialist care with 
a degree of success and that has provided the bases for most modern medical coding 
system (93, 94). Despite these efforts, follow up in diabetes remained suboptimal, resulting 
in preventable morbidity and mortality. In order to overcome this failure, there was an 
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increasing desire to find a robust method to establish and maintain a diabetes register. The 
St Vincent declaration (95) provided this platform to encourage health services to upgrade 
their systems in order to meet the targets of improvement in morbidity and mortality that 
was set in the declaration.  In the first validation study by Coulter et al, diabetes was found 
to be the most accurately recorded chronic disease in the general practice register (91) but 
this was only done by the primary care prescription records matched with the diabetic 
register patients and match was found for 72% of people. In order to meet the 
recommendations of Department of Health (DOH) and British Diabetes Association (BDA), 
the establishment of a district diabetes register to facilitate the systematic population based 
assessment of care delivery outcomes, and to ensure effective, efficient and equitable 
health care services, was considered to be a fundamental requirement. However, in order to 
establish a district wide centralised diabetes register, there is a need to establish linkages in 
systems between primary and secondary care datasets. One of the earliest attempts made 
to link primary, secondary and pharmacy data showed that there were huge gaps among 
different datasets and this highlighted difficulties in establishing such register. It was found 
difficult to devise an effective strategy to overcome these data gaps, and hence makes it 
difficult to deliver effective health care in a local health economy (96). At the same time, 
significant improvements were observed in the delivery of structured diabetes care, with 
the establishment of a district diabetes register by either sharing primary and secondary 
care data or central linkages of record specific for diabetes and it was acknowledged that 
the establishment of such register was feasible and important (97, 98). Coding errors were 
found to be the most common cause of discrepancies in the datasets, possibly due to lack of 
training, insight or multi source input. However with improvements in the coding system 
and data capture facilitated by the information technology, the establishment of a robust 
diabetes register by establishing multiple database linkages was further explored in 
Scotland. In the DARTS (Diabetes Audit and Research in Tayside Scotland) study, a unique 
patient identifier was allocated to people with diabetes on GP register. Details of these 
individuals were cross checked against eight independent data sources, as follows: Diabetes 
prescriptions database generated by the Medicines Monitoring Unit; Four datasets from 
various hospital diabetes clinics; Data from a mobile diabetes eye unit; the regional 
biochemistry database; the Scottish morbidity record; and it has not only exposed gaps 
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among different data sources but also identified previously undiagnosed patients.  This 
study proved that a robust centralised diabetes register can be established and used not 
only to plan and deliver health care but also to find people with diabetes who missed from 
mainstream registers (99). This was a large scale study that included mainline datasets in 
Scotland and provided a valuable insight into the utility of a centralised register. As the 
Scottish healthcare system is different from the English system, key question remained as to 
whether this study could be reproduced in any other parts of the UK.     
Like any other service, maintaining an accurate register for an ever changing population can 
be tedious work that relies on the motivation and enthusiasm of the service providers. The 
main deterrents include poor data sharing between primary and secondary care, problems 
with case ascertainment, patient migration, and discrepancies resulting from multisource 
data input and acquisition. This issue of motivation was addressed by introducing QOF, with 
related financial incentives to maintain an accurate diabetes register of the practice (59). 
This showed significant improvement in data capture across all chronic diseases including 
diabetes and also helped in improving care process completion in diabetes (60). The quality 
of primary care diabetes registers has improved to such an extent that it is used as the most 
accurate database to provide information about people with diabetes to national retinal 
screening programme (100) as well as National Diabetes Audit (28). 
However, despite all the progress made in this field, the fundamental concept of district 
diabetes register remained the source of demographic details of people with diabetes, 
although with the advancement in technology, it is perfectly possible that such a database 
can be used as a tool to plan and deliver health care pro-actively. It can be used to risk 
stratify people with diabetes and target care to those who needs it the most.  Scotland has 
shown a significant improvement in this area by establishing a regional centralised 
electronic diabetes register containing information about all people with diabetes in 
Scotland (101). Unfortunately, due to increasing fragmentation in the English NHS and lack 
of management support, this type of data integration has not been observed anywhere in 
England and Wales.  
In Wolverhampton, we have tried to establish an electronic centralised diabetes register 
that is accurate, and able to capture all nine key care processes in diabetes across the whole 
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local health economy. We have also described a detailed method of how to validate such a 
database and it is a first demonstration of an algorithm that can be used to ascertain 
accuracy of a diabetes register on rolling bases.  
Methodology of validation of the register 
The Wolverhampton District Diabetes Register (WDDR) is a historic patient record system 
(dating back to 1990) for people with diabetes. It was incorporated into an electronic 
database based on the ‘Diabeta3’ system in year 2000. Since 2008, the diabetes retinal 
screening programme, and more recently the local foot screening programme, are all run 
through this database – thus so it is an integrated system that was strategically developed 
precisely to ensure integration of data. It links to the local hospital Patient Administration 
System and Pathology System, and its data accuracy is checked against the NHS strategic 
tracing service (NSTS), also known as Demographic Batch Service (DBS). Information from 
individual primary care practices is separately accrued into a central data warehouse that is 
used as our local Primary Care Database (Figure 2.1).  
Fig. 2.1: Multiple data inputs in electronic centralised diabetes register. 
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To establish a centralised diabetes register, a starting point could be to merge data from 
both historic hospital diabetes register and primary care data set into one electronic register 
and then identify the data gaps between the two datasets. These gaps can then be 
investigated to produce a complete central dataset. Locally, to align the WDDR to the local 
Primary Care Database, demographic data on all alive patients coded as having diabetes 
from all 55 GP practices in the local area were extracted and uploaded into the WDDR in 
2009. Individuals previously not known to the WDDR were subsequently registered. All live 
people registered in the WDDR who were not in the GP database were identified, and a 
questionnaire was sent to their GP practices to obtain information on diabetes diagnosis 
and demographics. 
All GP practices responded to this questionnaire, and information obtained was updated on 
the WDDR. People who were not known to have diabetes in the GP database were subject 
to further biochemical cross checks (previous laboratory results) to verify the diagnosis of 
diabetes (according to WHO criteria). The WDDR was then updated, and GP practices were 
informed about any discrepancies for similar updating of their records (Figure 2.2). For non-
identifiable patients, further demographic checks were undertaken with the DBS to confirm 
demographic details, after which a confirmatory check with the GP practice and/or the 
individual if necessary was made. The data were then updated in the WDDR. Finally, we 
designed a scoring system, termed the Composite Access Score (CAS), based on three key 
diabetes access parameters – HbA1c, urine ACR and retinal screening with a score of 1 being 
awarded for each item if done within the last 15 months. This CAS scoring was applied to 
the validated diabetes register to assess its utility in predicting whether an individual is in or 
out of the area, and this helped to develop a model for validating the WDDR post extraction 
of information from the GP database and DBS. A score of zero would indicate that the 
patient has either not been active in local diabetes care or has defaulted care (Figure 2.3). 
After establishment and the initial validation process, in 2009, we acquired a complete 
demographic dataset. To make it useful, it was of the utmost importance to capture 
information of all nine key care processes in diabetes. After negotiating a data sharing 
agreement between primary and specialist care, the electronic database was enabled to 
capture this information from all available sources, as described above in November 2013. A 
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full set of revalidation process was repeated at this stage, to bring data to >95% accuracy. 
Once this data flow was established, the complete set of individualized diabetes specific 
parameters required to deliver structured diabetes care were captured in the database. This 
database was then used as basic prerequisite to develop a data driven modern healthcare 
delivery model-The WICKED Model of diabetes care.     
Since November 2013, a quarterly cycle of revalidation process has taken place to monitor 
the entry into the diabetes register, such as new diagnosis and people who move in the 
area, while exits from the register, including deceased patients and people who move out of 
the area are updated regularly. This regular cycle of quality improvement helps to keep the 
errors to a minimum level and to establish a high quality validated database. All new people 
diagnosed with diabetes are uploaded on a monthly basis after cross validating their 
diagnosis against biochemical tests and those who don’t fit the criteria are removed from 
the register and their GPs are informed. This enables the database to run at a high degree of 
accuracy.  
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Fig. 2.2: The process of cross checking GP Databases with a central diabetes register. 
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Fig. 2.3: The process of further demographic checks amongst people with diabetes not 
registered with local primary care. 
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Results 
The results of the systematic process of validating the WDDR post data extraction from the 
GP database are summarised in Figures 1 and 2. The number of live patients with diabetes 
from the region in the WDDR and the GP extraction were 15 653 and 13 305 respectively. A 
total of 217 from GP databases were not known to the WDDR, and were subsequently 
registered.  
In comparing the two registers (Figure 2.4), 13 088 individuals were in both databases; 2565 
individuals in the WDDR were not identified in the GP database, in which further processes 
of validation were undertaken.  
Of these 2565 patients in the WDDR who were not in the GP database, information on 2380 
individuals was obtained by contacting their named GPs, all of whom responded. The 
response from GPs confirmed 1244 as being registered with them and having a diagnosis of 
diabetes. Their data were previously not transferred by the GP practices to WDDR data 
transfer, because of coding errors. These errors were identified, corrected and updated by 
locating breaks at multiple points of data transfer. There were 93 patients in GP databases 
who were correctly coded as either impaired glycaemia or gestational diabetes, and 61 
patients were deceased. This information was updated in the WDDR. 
There were 742 individuals with no identifiable GP. Biochemical checks on 240 people 
registered in the WDDR as having diabetes, but not confirmed by their GP, showed diabetes 
in 47 individuals and the GPs were informed. There was no suggestion of diabetes in 126 
people, and 67 had either impaired glycaemia or previous gestational diabetes. These were 
updated in the WDDR. Thus, an initial 185 and a further 742 known to the WDDR had no 
identifiable GP. Therefore, altogether, 927 individuals with no identifiable GP practice were 
subject to DBS checks (Figure 2.5). A total of 237 were confirmed to be in the region but 
with a different GP practice, 422 with an identifiable GP out of area, 48 deceased and 220 
had no identifiable GP practice. The 457 patients who were in the area were again 
approached via the GP and by direct patient contact, and this confirmed 238 in the area, 7 
deceased, and 212 with no identifiable GP or had possibly moved away. 
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Overall, the WDDR numbers fell from 15 653 to 14 829 (n= 824: deceased -116; moved away 
-422; misdiagnosed -286) while the GP data rose from 13 088 to 14 617 (n= 1529: miscoded 
-1244; not known to GPs -285). Ultimately, only 212 of 14 829 (1.4%) on the central register 
were left unaccounted for, meaning we could not identify their GP or their status by any 
methodology. In this small group, we applied the CAS and found 99% had CAS=0 with only 
two individuals with a CAS of 1, essentially confirming their inactivity in local diabetes care 
provision.    
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Fig. 2.4: The results of cross checking GP Databases with a central diabetes register. 
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Fig. 2.5: Further demographic checks amongst people with diabetes not registered with 
local primary care. 
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After repeating the whole validation process in November 2013, there were 16,693 live 
patients in the Wolverhampton Clinical Commissioning Group (WCCG) area. The full results 
of this process are shown in (Figure 2.6). This was the baseline population recruited into the 
randomised control trial at the beginning of December 2013. 
From November 2013 to November 2014, there were 1037 patients added in as newly 
diagnosed with diabetes. 954 were diabetic, and 86 were not diabetic and were 
subsequently removed. With repeated validation and database cleansing cycles, the number 
of people registered as having diabetes due to coding errors have reduced from 985 to 388, 
gestational diabetes and impaired glycaemic states reduced from 598 to 178 and 86 to 25 
respectively. 388 people died during the year, and were removed from the register 
accordingly (Figure 2.7). 
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Fig. 2.6: Results of validation flow process in November 2013 
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Fig. 2.7: 12 months’ outcomes of continuous quarterly revalidation process of centralised 
diabetes register  
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Discussion 
We have learned from this exercise that no single database can be fully accurate. It is 
difficult to maintain the accuracy of any database, due to the dynamic demographics of the 
population and limitations of electronic record sharing systems. The NHS Spine similarly 
faced several problems with its summary care record as a result of discrepancies, due to 
technical errors in patients’ data uploads (102). However, since any such database can be 
crucial to service provision to the patients, we suggest that all local services should have a 
robust plan of validation that ensures a rolling mechanism of demographic cross checks 
from the DBS and GP databases at regular intervals, so as to reduce the number of 
discrepancies. This identifies people with diabetes who have either moved out of the area, 
or have moved from one GP practice to another, those who have died, those who are 
miscoded and those who do not have diabetes at all. 
GP coding errors were found to be a major cause of discrepancy. This relates to the multiple 
Read Codes used by the GP clinical computer systems. The NHS Information Authority 
generates Read Codes regularly, but GP computer system providers can also use different 
Read Codes for the same condition (103). In our validation process, a significant proportion 
of the discrepancy in our central database was found to be due to coding errors in primary 
care systems. There are multiple points where coding errors can happen, including 
completeness of data at input (GP practice level) or extraction of data by software that does 
not recognise all possible codes. Some patients were coded as having diabetes in GP 
systems but not known to the WDDR. One reason was that on our first match, our list of 
codes was incomplete. A complete list of these codes can be updated at regular intervals to 
avoid these discrepancies. Other coding discrepancies were mainly impaired glucose 
tolerance (IGT) and gestational diabetes (GDM) against diabetes diagnosis. These were all 
cross checked (including confirmation of the biochemical diagnosis) and corrected. Some 
patients were known to the register (through its triangulation with other systems [diabetes 
retinal screening, hospital PAS and pathology]) and, again, all of these were individually 
reviewed. Wherever such discrepancies were found, miscoding in the prime GP system was 
the most common cause of error. Completeness and correctness of data also rely heavily on 
the enthusiasm of practices and individual GPs (104). In our experience, there were a 
significant number of people with diabetes in GP practices who were not identified at our 
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first GP contact, but when, after demographic checks, we wrote back to the GP practices 
they managed to identify these patients on their lists. 
There is a need for standardisation of Read Codes so that all people with diabetes can be 
identified in the electronic record system to construct and maintain a valid diabetes register, 
since the quality of diabetes care depends on correct identification of these patients. One 
such example is the retinal screening programme that extracts its data from the GP2DRS 
system and relies on GP databases to identify people with diabetes. To achieve national 
standards of retinal screening, a database that is validated from multiple sources on a 
regular basis is vital. A recent NHS diabetes report has concluded that 85–90% of primary 
care data on diabetes are fit for purpose, but there is room for improvement (105). These 
coding errors, once rectified, will improve the quality of data feed in both the WDDR and 
GP2DRS databases. 
The Composite Access Score is a very useful tool to identify patient access to diabetes 
services. When applied to individuals who were not identifiable by GP database, DBS and 
direct contact, it had a strong predictive value in identifying people who had moved away. It 
can also be used to identify people with diabetes who are not engaged with the services. 
Three key elements of this score, namely HbA1c, urine ACR and retinal screening will 
incorporate all the process modalities (blood test, urine test and contact with screening 
programme) a patient should have as a part of their routine diabetes care. The National 
Diabetes Inpatient Audit (NaDIA 2010–2011) report suggested that failure to complete nine 
care processes could deprive people of timely intervention to prevent complications (28). By 
applying a CAS score to all patients on a district diabetes register, all non-engaged people 
can be identified, and a proactive approach can be adapted to get these patients involved in 
their diabetes care. 
Biochemical checks could be utilised effectively to validate a database and to populate 
relevant registers such as the WDDR, IGT and GDM registers. This will help to identify 
accurately people to whom to offer correct management advice according to their status of 
diabetes or pre-diabetes. This failsafe process minimises the chances of inadvertently 
removing an individual from the register purely based on information available from GP 
data extraction that may not be always accurate (Figure 2.8). 
 
64 
 
This entire process of data validation is tedious and labour intensive, albeit worthwhile. 
Once a valid database is established after going through all of this hard work, it is easy to 
maintain it by cross checking details with other databases at regular intervals. Up until 2012, 
this database mainly held demographics, biochemical test results, retinal screening and 
partly foot screening details. Only those attending hospital diabetes clinic were recipients of 
their other processes (like weight, BMI, smoking status, vascular risk and foot risk) captured 
in this register, but those who were under their GP care were not included in the database. 
This lack of data integration was considered a key barrier in delivering integrated diabetes 
care across any local health economy (89).  In 2013, we extended the data input to this 
register to include all key care processes data capture of all people with diabetes in 
Wolverhampton, regardless of the location of the care delivery. Hence, we now have the 
ability to acquire all the information in our accurate database updated on weekly basis with 
rolling cycles of validation at least quarterly. During each validation cycle all processes 
described above are carried out to a high standard of accuracy. All newly diagnosed patients 
are uploaded in the database on a weekly (80% of the practices) or monthly (20% of the 
practices) basis. Before their data entry into WDDR their diagnoses are cross checked 
against biochemical markers to ensure accuracy of the database. All discrepancies of 
diagnosis are then communicated back to the GPs to seek further clarification. The number 
of discrepancies in follow up checks has significantly reduced, making it a quick and cost 
effective process. This has not only improved the completeness of key care processes, 
including retinal and foot screening programmes, but has also helped us to plan our service 
delivery and resources according to the needs of the population. After this whole process of 
validation, we now have a >97% accurate district diabetes register in Wolverhampton.     
This register can have wider implications in terms of assessing the severity of the diabetes 
epidemic. During the last year, despite adding over 1000 newly diagnosed patients the total 
size of the register didn’t expand above 700 patients due to quality improvement processes 
in place for validation of this register. These processes of keeping the register updated are 
described above, and showed in figure 2.7. This equates to nearly 30% of the disease burden 
that may result in spuriously high disease prevalence and can potentially have direct 
implications on resource management and strategies to tackle this disease. National 
datasets like Health and Social Care Information Centre (HSCIC) show the prevalence of 
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diabetes based on the crude datasets from primary and perhaps specialist care, and without 
validating these datasets estimated diabetes prevalence in a specified area could be higher 
than actual prevalence. If we compare the expected prevalence range for our local health 
economy against HSCIC data sets, it would have been accurate if this work of validation of 
database would not have happened. There may be a need to address the accuracy of such 
national datasets that dictate national policies and direct resources by introducing such 
revalidation processes. 
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Fig. 2.8: Proposed Algorithm 
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Chapter 3: Access to Health Care 
Background 
No one would deny that even the most efficient healthcare delivery service in the world can 
only be successful if patients are actually accessing the service. Even with the best will in the 
world, there must be an interaction between the person with the disease and the health 
services, in order to initiate and support disease management. This concept of access should 
neither be confused with other issues such as default from care, nor considered the sole 
responsibility of person with the disease. It is, and should be taken as the joint responsibility 
of healthcare service, clinicians and patients to ensure that every one should be able to 
access the service to gain maximum benefit in their disease management. Therefore, the 
concept of access to health care should not only be well understood but also embedded as a 
fundamental necessity to ensure success of a healthcare delivery model. 
The birth of the NHS was based on 3 core principles: that it meet the needs of everyone; 
that it be free at the point of delivery; that it be based on clinical need, not ability to pay. 
Nonetheless, health inequalities in United Kingdom were identified in the Black report in 
1980. Key findings of this report showed that there were large differences in morbidity and 
mortality that favour higher social class and they were not addressed by health or social 
services (106). This report generated a major debate among health economics to try to 
define and explain the principles of equity and justice in health care.  Over a period of time, 
several conflicting definitions of equity in healthcare have emerged that include “equality of 
expenditure per capita”, “distribution according to need”, “‘equality of access” and 
“equality of health” (107),(108, 109).  Two of these definitions t based on the concept of 
“need” and “access” were explored in depth by Culyer and Wagstaff (110). Although it may 
seem to be a rather simple concept that healthcare should be distributed according to the 
needs of the patients, it has two different dimensions. Horizontal equity represent the 
equality of treatment for people in similar needs and vertical equity argue that people who 
have different needs should be treated differently (111). However, need can be judged 
either at the time of initial contact with the patient and people who are more ill than others 
should receive quicker treatment (112, 113), or it can be judged on the principal of capacity 
to benefit (114). A judgment regarding this capacity to benefit needs to be made very 
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carefully by keeping the holistic approach to balance the benefit against resources and 
capacity of health care system.  
The concept of access to healthcare is also important to understand, as it can sometime be 
coupled with the concept of need; that people who have different needs should have 
different level of access to healthcare and this will again bring the horizontal and vertical 
versions of access similar to that of equity as described above. Access means that people 
should be able to avail themselves of a facility when they need it or want it. It is sometimes 
used with the term utilization (115, 116) but others consider that access can be taken as a 
forgone utility or a cost incurred in receiving healthcare (107) or maximum attainable 
consumption (117).  
Justice in healthcare may be explained under four fundamental principles. “Need 
principles”, are most widely discussed, as evident from the above discussion, and advocate 
treatment of patients based on their needs. According to “Maximising Principles”, justice in 
health requires that care should be distributed to achieve best possible consequences. A key 
issue with this approach is that how can we quantify and predict the maximum benefit 
during the course of an illness or wellbeing of people. Reduction in inequalities of 
healthcare to the least advantaged people can be used as a single point of focus if we follow 
“Egalitarian Principles” although to utilise its maximum benefit one might want to use them 
in combination with maximising principles. Finally, all these principles can be used in 
combination to elaborate “Combination Principles” to apply various components of all other 
principles in a structured manner. However, the biggest issue would be how to maintain a 
balance when applying the combination principles and one way to deal with this is to keep a 
primary principle as a core strategy backed up by the second principle when first one fails to 
yield the answer (118).    
Despite all efforts to eliminate inequalities from healthcare the findings of 10 years follow 
up of Black report (119) showed that these inequalities still existed. Therefore, it deemed 
necessary for the NHS to formulate a shared ethical code for everybody in health care to 
follow. This resulted in the emergence of a draft of ethical principles known as the Tavistock 
principles in 1997. This consisted of 5 fundamental principles that should govern the 
healthcare system (120). They were as follows: 
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1. Health care is a human right  
2. The care of individuals is at the centre of healthcare delivery but must be viewed and 
practised within the overall context of continuing work to generate the greatest 
possible health gains for groups and populations. 
3. The responsibilities of the healthcare delivery system include the prevention of illness 
and the alleviation of disability.  
4. Cooperation with each other and those served is imperative for those working within 
the healthcare delivery system.  
5. All individuals and groups involved in health care, whether providing access or 
services, have the continuing responsibility to help improve its quality. 
These principles generated a debate about rights, balance, comprehensiveness, co-
operation, improvement, safety and openness across the world (121) and elicited a degree 
of criticism (122). Eventually, after refinement and implementation, these principles were 
widely accepted not only in the NHS but also worldwide. These principles set the tone for 
the healthcare system to take overall responsibility to ensure that people should be able to 
access a high quality service to prevent and treat their illness and strive to achieve 
excellence in care and health gains for the population.   
Despite the introduction of NSF and QOF to improve and support the access to healthcare 
there are huge geographical variations in the attainment of key care processes in diabetes 
(26).   
In order to further understand this concept of access, I undertook a case controlled study to 
determine factor that affect Access to healthcare.  
There is no known validated tool to identify failed patient access to diabetes health care. 
Within the validation process of our local diabetes data set (123), a scoring system was used 
to assess the level of access of patients to diabetes services – predominantly as a 
mechanism to determine those who were or were not still active participants in local 
diabetes care in order to maintain the epidemiological accuracy of the local diabetes 
register. We undertook a case control study of patients with diabetes, identifying and 
comparing those with complete or incomplete access criteria according to a score that we 
 
70 
 
renamed, the Failed Access Score (FAS). The objective of this study was to determine 
whether this score identified access failure that can be attributed to identifiable factors 
among individuals with diabetes. 
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Aims 
To determine what factors can affect patient access to diabetes care. 
To determine whether a scoring system can be used to identify people who are failing 
access to diabetes care. 
Hypothesis 
By using a scoring system, failed access to diabetes care can be flagged and the barriers that 
results in poor patient engagement can be identified. 
Methods 
The Failed Access Score 
The FAS consists of three key care processes in diabetes, these being HbA1c, urinary 
albumin:creatinine ratio (ACR) and retinal screening. This maps to all domains of diabetes 
care processes in the form of: a blood test (HbA1c) – meaning that all blood tests could have 
been done; a urine test (ACR) – meaning that the patient attended a clinical appointment so 
that all clinical measures could have been completed; and a retinal screening test – 
confirming that the patients are in receipt of communication and able to engage in self-care. 
Each of these parameters is universally captured in the central database wherever 
undertaken, whereas others may not be (e.g. weight, blood pressure etc). Completion of all 
three processes is indicative that the patient has access to the service and engaged to the 
extent that sufficient opportunity exists for health services to complete all nine key care 
processes in diabetes. The failure of any one parameter over the preceding 15 months was 
scored 1. A score of zero meant that all three parameters were completed, while a score of 
3 meant maximal failure of access such that none of the three parameters were completed 
and there was no access to the service. 
Study sample 
The study was undertaken in a single, large inner city GP practice. A retrospective case 
control study was undertaken on all the patients in this practice who failed more than one 
FAS parameter in the last 15 months, meaning they had a FAS of 2 or 3. They were 
compared to those with no access failure (FAS = 0) matched for age, gender, ethnicity and 
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type of diabetes as controls. All data were extracted from EMIS-Web primary care computer 
system. All identified factors were categorised either as patient or service related. Patient 
related factors were further subdivided thus: those related to non-attendance, care refusal 
or unavailability (moved away); or clinical and social issues that were a barrier to the patient 
attending (palliative care, house bound, mental health issues, multiple comorbidities, 
language barrier). Service related factors simply represent pure service failure in otherwise 
attending patients. 
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Whole population analysis 
Further analysis of FAS was undertaken on the whole district population using data in our 
local integrated diabetes register. This analysis is served to highlight the fact that failed 
access can potentially be identified by using this score and we may take this small sample of 
the pilot study to speculate numbers of people in various categories of failed access to 
healthcare. However, this did not contain sufficient detail to drill down to constraints 
identifiable at the individual level as identified in the single practice survey.  This can 
potentially be a full project in its own right, to identify and further explore the barriers to 
access. 
The English Indices of Deprivation provides a relative measure of deprivation based on a 
group of 10 different indices that all measure different aspects of deprivation. The most 
widely used of these indices is the Index of Multiple Deprivation (IMD) which is a 
combination of a number of the other indices to give an overall score for the relative level of 
multiple deprivation experienced in every neighbourhood in England.  It involves complex 
calculation methodology but a report based on small areas in England is produced regularly 
by the Department of Communities and Local Government. 
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Results 
From a practice size of 6322, there were 478 registered with diabetes (prevalence 7.6%) of 
whom 51 were identified with partial or complete access failure by a FAS score of 2 or 3 
(n=43 [84%] and n=8 [16%] respectively). 
Of the 51 cases: ACR was missing in 72%; HbA1c in 42%; retinal screening in 34%. The 
demographic characteristics of the cohorts are presented in Table 3.1. The groups were 
matched for all a-priori selected demographic criteria but in post-hoc analysis the failed 
access group had a higher deprivation score. Reasons for access failure are given in Table 
3.2. The service failed to complete the processes of diabetes in those who were regularly 
attending in 12 patients (24%). Eighteen (35%) patients had not attended despite 
documented multiple recall communications or had moved away, and we judged the 
practice could not have done more about these. However, 21 (41%) patients were 
constrained from access because of poor mobility, mental health issues, palliative or end of 
life care or comorbidities. Excluding those where service failure caused access failure (n=12), 
among 39 patients compared to controls, there was a significant difference in the 
proportional distribution of those constraints (χ2=49.9, p<0.001) with a greater number of 
those house bound, with mental health issues, or in palliative care, although multiple 
morbidity in its own right was not associated with access failure. In the whole local health 
economy (Wolverhampton Clinical Commissioning Group), there were 16 644 registered 
patients with diabetes and their demographic and other data are given in Table 3.3. With 
increasing FAS, there were significant rises in age, male gender and deprivation score and a 
decrease in the prevalence of type 2 diabetes or, conversely, an increase in the prevalence 
of type 1 diabetes. Ethnicity data were incompletely recorded, but where known the 
association with increasing failures of access was nevertheless significant, and the 
prevalence of non-Caucasian ethnicity rose to 36% with a FAS of 3 from a baseline of 18% in 
those with a FAS of zero and/or in the whole population. In regression analysis, these 
factors were all significantly associated with the FAS (χ2=303.9, p<0.001) but they explained 
very little of the variance in FAS – about 2% (r2=0.018) – such that the model was incapable 
of predicting individual access failure (<1% accuracy). In extrapolating the findings from a 
single practice to the 2362 patients across Wolverhampton with FAS of 2 or 3, there would 
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have been 567, 827, and 968 patients with access failure due to service failure, repeated 
non-attendance, or co-existing clinical or social issues, respectively.   
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Table 3.1 
The demographics characteristics of cases with failed access to diabetes care compared to 
those matched controls with full access (mean ± SD or number (%)).  
 
 
 
  Cases Controls P 
  51 51  
Age years 62 ± 17 61 ± 16 Ns 
Gender males  31 (61%) 31 (61%) Ns 
Ethnicity Caucasian 20 (39%) 21 (41%) Ns 
 Asian 23 (45%) 26 (51%)  
 Black 6 (12%) 4 (8%)  
 Unknown 2 (4%) 0  
Duration Diabetes years 11 ± 8 11 ± 7 Ns 
Type Diabetes  type 2 48 48 Ns 
Insulin use   15 16 Ns 
Deprivation Score  40 ± 15 31 ± 16 0.009 
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Table 3.2 
 Constraints to access to diabetes care identified in cases and control groups (number (%))
  
  
 
 No 
constraint 
Process 
failure 
Non 
responder 
Moved  Language 
barrier 
House 
bound 
Multi-
morbidity 
Mental 
health  
Palliative 
care  
Controls 51 39 (77) 0 0 0 0 2 (4) 7 (14) 3 (6) 0 
Cases 51 0 12 (24) 11 (22) 5 (10) 1 (2) 6 (12) 1 (2) 8 (16) 5 (10) 
Service 
Failure 
12 (24) 0 12 (100) 0 0 0 0 0 0 0 
Non-
service 
modifiable 
18 (35) 0 0 13 (72) 5 (28) 0 0 0 0 0 
Service 
modifiable 
21 (41) 0 0 0 0 1 (5) 6 (28) 1 (5) 8 (38) 5 (24) 
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Table 3.3 
Whole district analysis of factors associated with the Failed Access Score (FAS).  
 
 All FAS= 0 FAS= 1 FAS= 2 FAS= 3  
 16644 10171(61%) 3999 (24%) 1547 (9%) 815 (5%)  
Age 64±15 65±14 63±16 61±18 58±17 F=84.5 
p<0.001 
Male  9030 (54) 5558 (54%) 2121 (53%) 815 (53%) 475(58%) χ2=43.8 
p<0.001 
Ethnicity 
White,  
Asian,  
Black,  
Other  
Unknown 
 
4475 (27%) 
2104 (13%) 
699 (4%) 
216 (1%) 
9150 (55%) 
 
2879 (28%) 
1307 (13%) 
427 (4%) 
49 (1%) 
5505 (54%) 
 
1069 (27%) 
456 (11%) 
147 (4%) 
37 (1%) 
2290 (57%) 
 
367 (24%) 
186 (12%) 
76 (5%) 
41 (3%) 
877 (57%) 
 
160 (20%) 
155 (19%) 
49 (6%) 
89 (11%) 
362 (44%) 
 
 
χ2=748.8 
p<0.001 
Type 2 diabetes 15575(94%) 9620 (95%) 3746 (94%) 1454 (94%) 755 (93%) χ2=8.5 
p<0.05 
Deprivation score 35±16 34±16 35±16 37±16 37±16 F=26.7 
p<0.001 
HbA1c missing 1838 (11%) 0 286 (7%) 737 (48%) 815 
(100%) 
χ2=9939.7 
p<0.001 
ACR missing 4616 (27%) 0 2372 (59%) 1492 (92%) 815 
(100%) 
χ2=11195.2 
p<0.001 
Retinal Screening 
missing 
3084 (18%) 0 1341 (34%) 928 (60%) 815 
(100%) 
χ2=8211.4 
p<0.001 
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Discussion 
 We have demonstrated that readily available data can be easily used to identify people 
with diabetes who have failed access to structured diabetes care. Having flagged this risk, 
we have proposed a framework for the categorising the primary factors leading to access 
failure: service failure, non-attendance and patient related clinical and social issues. In the 
latter category, a further classification substructure emerges that indicates the prime 
reasons that might well require a specific individualised care plan. Therefore, access is 
complex, but one of the founding principles of any healthcare delivery model.  Access 
however should not be confused with or use as a synonym of “default” or “loss to follow 
up”. It has been shown that people can default from care due to several reasons. This can 
be a simple misunderstanding in terms of seeking medical help when deemed necessary as 
compared to the need for monitoring to help prevent complications (124). Attitudes 
towards the disease as well as clinic, obesity, young age and type of treatment were also 
found to be important factors in defaulters (125). There is a particular stigma attached to 
these terms that leads to a sense of unease and a bias in the minds of healthcare 
professionals, as the burden of default lies with the patient and considered as a hallmark of 
non-serious behaviour or disengagement from the service.   
However it is extremely important to separate an informed dissent from care to 
multifactorial issues that put people at a disadvantage in complying with scheduled care.  
Therefore a broader concept of access to healthcare needs to be understood in the context 
of needs that can be broader than those that are related to a particular illness. Mostly 
patient related factors are considered to be the main reason for default, the specific nature 
of the influence of the factors that were identified is often elusive. Considering that younger 
people are more likely to default but whether it is because they just do not care, or whether 
it is related to their affordability to take time off from work or school to attend the clinic or 
they do not like paternalistic attitude of clinicians in the clinic resulted in dissatisfaction and 
appear as waste of time. People experiencing stress and anxiety related to their disease 
(126) as well as those who lack basic resources like a telephone or a car are more likely to 
default (127). Prolonged waiting times, increasing parking costs, inability to book or afford 
child care are also found to be considerable confounding factors in promoting 
nonattendance (127). Considering such a diversity of factors relating to default tailor made 
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individualised approaches needs to be taken to address the concerns and needs of patients. 
In order to understand the concept of access, there is a need of effective communication, 
patient centricity, a review of health –system factors such as operational hours, distance to 
the clinic and waiting times, and as further research to elaborate other factors resulting in 
default from care is needed to understand the concept of access (128).    
In our study, we proposed a data driven method to identify people with failed access that 
may require specific and individualised method of care delivery to meet the needs of these 
people at disadvantage. Executing this process requires a model of care that is integrated 
across NHS providers, and organisational and care pathway divides. The WICKED 
(Wolverhampton Interface Care, Knowledge Empowered Diabetes) project aspires to be a 
system of structured diabetes care that is patient centric (129). This shifts the notion of 
integration of care provision from between services to integration around the patient (71, 
73, 130).Crucial to this is data integration and the effective use of those data to target 
patients at risk. Achieving access is a key objective (131). In simplistic terms, process and 
outcome cannot be delivered without access. Access failure may relate to service structure, 
capacity, accessibility, availability and efficiency, or a number of patient related factors such 
as language, culture, social capital, social status and deprivation as well as physical and 
mental health (132-134). What is clear is that it is not easy to predict access failure (135). 
Yet failure of access is clearly associated with adverse outcomes (136), although whether 
enhancing access improves outcome is not clear. As a single measure, we demonstrate that 
the FAS can be used to identify and target actual access failure. This allows access 
attainment to become a hard outcome that can be subject to review, audit, governance and 
performance management. A further simple data drill down can determine those in whom 
service failures have occurred and those who do not wish to access the service (137). 
Regarding the latter, it is the choice of an informed and competent adult as to whether to 
engage or disengage with health care services. This choice may be influenced by many 
factors, but any such choice should be respected. We emphasise that a health care service 
must ensure that a person is fully aware of the consequences of disengagement before 
labelling them as having informed disengagement, and that it is not the intention of the FAS 
to simply identify those who are to be exempted from care. The FAS can identify such 
patients and help get beyond the simple concept of ‘default’. The FAS particularly applies to 
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those identified with associated social and medical problems. Mental health problems were 
found to be the most common of these constraints as is well known (132, 138). Other 
important groups were the house bound, those with comorbidities or those in palliative 
care. It was interesting to note that, when compared with the control group, comorbidities 
alone did not affect access until it was associated with dependency (139), and it is clear that 
such patients require an individualised care plan (140). 
Another interesting finding is that there was no significant difference between ethnicities 
unlike many other studies that shows significant difference in ethnicities (141). This may be 
due to the small scale of this study, which means that this issue is hidden. On the other 
hand, it may be reflective of a real change, where with the passage of time, the diversity and 
evolution of local population has improved awareness in ethnic minorities to seek help and 
to look after their chronic diseases equally well as compared to Caucasians.  
The strength of this pilot study is the highly matched control population and a standardised 
approach to data collection from one practice only, which will limit practice management 
and organisational bias. The limitations of the study are that it is small scale and only used 3 
out of nine key care processes to compile FAS.   However, since we conducted this study and 
upgraded our database to the capability to acquire information about all nine key care 
processes, we used the Failed Process Score (FPS) as a marker to measure patient access in 
our randomised controlled trial as described in forthcoming chapters. As FAS is a novel tool 
that has not been validated previously, it was difficult to estimate its accuracy to identify 
failed access. 
There is a scope for a future qualitative study not only to validate FAS, but also as to gain a 
deeper understanding of the barriers to access to health care. In this regard there is a need 
to identify people at a disadvantage by using data effectively but in order to meet their 
needs there should be a better understanding of the perspective of these groups to define 
what strategies could work best with the different categories of people to deliver an 
equitable health care service in the modern NHS. 
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As demonstrated by this study, a database can be used in a variety of ways to help improve 
diabetes care delivery and one aspect of it to identify access failure to inform healthcare 
systems to take steps to improve patient access. There are other potential arenas to utilise 
this database in a meaningful way to improve direct patient care. Therefore, there is a need 
to further explore impact of incorporating a data driven patient empowerment strategy to 
increase active involvement of the patient in their care, for example, care planning 
consultations. 
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Chapter 4: Patient Activation and Care Planning 
Background 
“Patient activation” is a relatively new concept that has been studied extensively in last 2 
decades (142). This terminology is better understood in the United States, where a lot of 
work has been done to explore the potentials of patient activation. However, the notion of 
patient activation has been synonymised in various terminologies like patient 
empowerment, patient enablement, self-care, patient engagement and patient centricity; 
across UK and has a longer history of understanding than the terminology itself. All these 
terms embrace the fundamental principle of active patient involvement in disease 
management. No one would deny that the patient who lives with chronic diseases has to 
execute their management plans on day to day basis. It is understandable that it can only be 
achieved effectively if the patients are active in their own disease management strategy. 
Therefore, in order to better understand this concept, we need to go through the 
underpinning principles and their evolution in the history of healthcare. 
The concept of patient involvement in diabetes is not new, and as discussed in the first 
chapter, very earlier pioneers in diabetes care like E. Joslin (44) and R D Lawrence (47) have 
acknowledged that effective healthcare cannot be achieved without the intelligent co-
operation of people suffering from the disease. However, this type of patient engagement 
requires a behavioural change from both parties i.e. patients and clinicians, in the 
consultation process (143). Traditionally, clinicians are trained on a medical model that 
focuses on the treatment of the disease, and can potentially overlook the holistic needs of 
an individual, and hence conflict with the notion of patient empowerment (144). This was 
based on the idea that the clinician knows best, and the patient’s part in the consultation 
was to follow whatever has been told as an obligation. The benefit of compliance would 
outweigh the quality of life matters for the patients. This approach in chronic disease care 
delivery such as diabetes did not work, and despite all advancement in medical treatments, 
achievement of optimal control remains well below expectations (145-147). 
Due to the evolution of information technology, people with chronic diseases have started 
to gain more information from multiple sources and growing evidence suggests that 
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people’s involvement in their own care results in better outcomes (148). This has pushed 
healthcare systems to adapt this notion of active patient involvement in the healthcare 
delivery processes. This shifts the balance of healthcare consultation from a compliance 
model to a collaborative model of care, whereby a consultation is called a meeting between 
experts (149). This approach focused on three key aspects of disease management; choice, 
control and consequences. People living with diabetes have to make a choice in their day to 
day decision making in order to control glycaemic variability. These choices need to be 
informed, and a person should be able to exercise control in making these choices. Patients 
have control to execute their management plan in whatever way they wish to do so and as 
they are directly affected by the consequences of their choices and control, they should 
have active involvement in designing their individualised management plans (150).    
This type of physician patient interaction has been evaluated from various aspects of 
improvement in hard clinical outcomes, behavioural change as well as patient satisfaction 
(148, 151-154) and was found to be effective. On the contrary, studies have shown that a 
patient empowerment approach may require a sustained length of time to show any 
benefits that can be as long as 6 years (155), and this may not be enough to produce a 
behaviour change (156). This empowerment may show an improvement in patient’s 
confidence, due to acquired diabetes knowledge, but may not be translated into either 
psychological (self-care, satisfaction) or physiological benefits (157, 158). However all these 
studies have focused on the outcomes of interventions in which patient were empowered 
by the healthcare professionals and facilitation came from them, rather than patient’s own 
initiatives or learning from information. 
The simple fact of prevalence dictates that without empowering people to self-care for 
themselves, no system in the world would be able to meet the resources required to meet 
the needs of this slow epidemic. Therefore, this concept of patient empowerment that is 
defined as “[a] process whereby patients have the knowledge, skills, attitudes and self-
awareness necessary to influence their own behaviour and that of others in order to improve 
the quality of their lives” (159) flourished further, to enhance people’s ability to self-care. In 
the NHS the terminology of “Expert patient” was embraced by primary care long before 
(149) it was introduced in the specialist care (160, 161). The Department of Health (DOH) 
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proposed implementation of this concept, which should encourage people to take a key role 
in the decision making of their care process and will promote self-care; across all chronic 
diseases by 2007. At the same time, user-led self-management requires a cultural change 
that was anticipated to be difficult to implement. In the USA, Kaiser Permanente had a 
legacy to promote this cultural change, to the extent that vast majority of their people with 
diabetes are self-caring and the resources are diverted to either shared care for people who 
are at intermediate risk and specialised care for people who are at high risk of complications 
to justify the equity of healthcare without undermining the quality of care needed for the 
whole epidemiologic base (162).  In the NHS, this concept of expert patient has met with 
mixed views. Those who are in favour of this policy see it as an opportunity to allow 
clinicians to build a rapport with their patients and a shared decision making will also 
facilitate the sharing of responsibilities and risks associated with the choices made in 
partnership with the patients themselves (163). It is also seen as a collaboration between 
users and providers where both are aware of their responsibilities and utilise this 
partnership to achieve best possible heath in given resources at hand (164). Others see it as 
a risk to the NHS, as the literal meaning of expert patient will provoke a conflict between 
healthcare professionals and the patients who can demand and argue for the things that are 
unsuitable, unproven or expensive, resulting in a breakdown of the patient-doctor 
relationship (165). This terminology has been criticised for lack of clarity, leading to 
misconceptions, with limited explanations of rights and responsibilities and a lacking of a 
strategy to challenge professionals’ assumptions towards chronic diseases (166).   
Patient activation is a relatively new term that incorporates six fundamental domains of self-
efficacy, engagement in health maintenance, involvement in management of disease, 
collaboration with healthcare providers, choose and access the appropriate services and 
ability to navigate the healthcare system towards improvement. Thus, Patient Activation 
(PA) is a behavioural concept that can be defined as “‘an individual’s knowledge, skill, and 
confidence for managing their health and health care” (167, 168). One of the earliest 
demonstrations that patient activation improves diabetes related outcomes was reported in 
the form of an RCT at patient discharge from the hospital, which showed that people who 
are activated had better functional status after discharge (142). This was a short scale study, 
which looked at functional status in people who were trained to self-care after discharge. In 
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its own right, this only explored one of the six main domains of patient activation. However, 
this along with other concepts of people empowerment helped to develop a better 
understanding of PA in future. 
This concept was further developed by Judith Hibbard in the USA, and to evaluate its 
impact, a comprehensive Patient Activation Measure (PAM) was developed in 2004 by 
adapting a robust methodology of literature review, expert consensus and piloting different 
phases of the scale (167). According to Hibbard et al., there are 4 levels of patient activation. 
At level 1, people with chronic illness tend to be passive in management of their own 
condition. This may well be due to lack of understanding of their role in the process of care. 
At level 2, with more activation, these people start to develop an understanding of their 
illness but lack knowledge and confidence to actively participate in their own care. At level 
3, by providing them with knowledge and information these people develop confidence to 
start making day to day decisions for managing their condition, but they may still not be 
fully independent in making these assessments. At level 4, with the time and support, these 
people can eventually gain maximum confidence to act in an appropriate way to manage 
them, but at this stage, the issue is whether this level of functional capability can be 
maintained in the long run, and any level of stress can derail this level of patient activation 
(169). People with higher level of activation see PA as being in control and in charge of their 
own health (169) and these people have shown benefits in term of less use of emergency 
care and hospitalization(170) , better hard clinical outcomes markers like HbA1C and Lipids 
(171), better health related behaviours and less Primary care services utilizations (172). 
Nonetheless, fewer data are available about its cost effectiveness (173).    
A meeting between an activated patient and a healthcare professional is supposed to be 
very productive and should produce a comprehensive management plan for the long term 
illness such as diabetes. This information can be captured in a written plan of care like 
“minutes of a meeting” as a care plan that can be taken as a written and mutually agreed 
agreement of care to guide future management plan of individual patient. Since the 
beginning of the 21st century, the DOH has promoted this concept of care planning to be 
incorporated as a routine process in all long-term conditions, including diabetes, with the 
vision that every one of the 15 million people with at least one long-term condition to have 
 
87 
 
an agreed care plan (174). At initial stages of implementation care plans were used as 
means to record a consultation and an agreed agenda that may help primary healthcare 
providers and patients to recall their last consultation but it was not very commonly used in 
multidisciplinary care provision (175) and its impact on diabetes outcomes were uncertain 
(176) but most of this evidence was from outside UK and was of small scale audits.   
In the UK, care planning in diabetes was incorporated as a standard of care in diabetes NSF 
(57) and in collaboration with Diabetes UK; one of the leading charity of people with 
diabetes; a care planning in diabetes document was produced in 2006 (177). This document 
guided the principles of care planning in long term conditions in general, but focused mainly 
on diabetes. It incorporated many national DOH initiatives of people’s involvement in self-
care like “Our health, Our care, Our say “(178) and “Supporting people with long term 
conditions to self-care: a guide to developing local strategies and good practice” (179). In 
this report, it was acknowledged that to promote care planning a change in behaviour will 
be required from healthcare professionals as well as patients, the care planning process is a 
two way communication, negotiations and joint decision making underpinned by the 
fundamental principles of patient centeredness and partnership working. To execute these 
principles successfully, the “Disease-illness model” was proposed to be implemented when 
looking after people with chronic diseases (180). This model encourages clinicians not only 
to look at a disease from illness view point, but also to try to develop an understanding of 
the individual’s experiences of that condition. This requires paying attention to patient’s 
“Ideas, Concerns and Expectations” (181); a term very well known to primary care clinicians 
but not so well to specialist services. However a systematic review in 2009 to assess the 
impact of personalised care planning in diabetes showed that there is lack of evidence that 
the process of care planning was either implemented in its true sense or showed any 
benefits in diabetes outcomes (140).  
In order to implement a comprehensive care planning process “Year of Care” pilot project 
was launched (130) across three sites in England. Key drivers of this projects was to develop 
a care planning strategy that can implement a personalised and tailored care plan that 
identify an individual’s needs, issues, concerns, goals and actions, and can manage the 
tension between what the health care professional and the person with diabetes may view 
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as good outcomes while ensuring a supportive organisational framework is in place to 
support the whole process.  Over 3 years this project has shown an improvement in number 
of care planning consultations, training of HCPs, improved experience, knowledge and skills 
of people with diabetes and has provided a platform  to implement care planning process 
across the wider NHS (66). 
However, despite these efforts, the implementation of care planning is patchy and can be a 
cause for concern for many HCPs. In practice, it might require an organisational change, 
shifts in attitudes and behaviours, large-scale education and training, extensive research, 
audit, evaluation and governance and, not least, funding. Sceptics may allude to this process 
as a ‘tick-box exercise’. For specialists, it may be considered something best left to primary 
care, who in turn may think they have enough on their diabetes agenda. As part of a 
modernising agenda in our local WICKED model of diabetes care, incorporating a further 
shift to patient centricity, we determined the feasibility of introducing a care planning 
process into our routine specialist diabetes clinics. This pilot also assessed utilization of a 
patient information provision tool to the patient to promote patient activation, as well as 
role of this tool in care planning process for future implementations. 
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Aims 
To establish that people with diabetes can understand a structured document mapped 
against all 9 key care processes in diabetes and can use it as a template in their consultation 
with healthcare professionals 
To establish that a structured document can assist healthcare professionals to standardize 
their consultation and enable them to do care planning and generate a care plan at the end 
of the consultation. 
Hypothesis 
A simple but structured document containing key care processes in diabetes provided to the 
patients before their clinic appointment can align the patients and healthcare professionals 
to participate in a care planning consultation with a view to generate a mutually agreed care 
plan. 
Methods 
A structured document was designed to facilitate a care planning process. A design group 
was established, including lay patient representatives, clinicians, a medical illustration 
expert, and a trained diabetes education facilitator (Expert Programme). National Health 
Service guidance for patient information materials was used to set design standards (All 
these processes are discussed in depth in the methodology chapter). The finalised 
document constituted a simple diabetes care planner mapped against all core diabetes care 
processes incorporating an adult reflective learning approach (182) driving a ‘Do, Review, 
Learn, Apply’ process focused on promoting understanding. It emphasised engagement, 
enablement and empowerment, with the intention of facilitating patient driven care. At this 
stage, the document did not contain individualised patient level information (such as their 
weight, HbA1c etc). This finalised document was piloted in 50 patients consecutively 
attending a general specialist diabetes clinic for acceptability. 
Following the results of this evaluation, the document (Table 4.1) was used in structured 
care planning, which was agreed and introduced into all of our routine diabetes clinics. The 
care planning document was given to 148 consecutive patients and a total of 12 clinicians 
participated in this one-week-long trial. All clinicians were consulted and orientated in the 
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process, and perceived challenges relating to alterations in routine consultation were 
highlighted and discussed with the intention of standardising the whole process. Every 
patient was given a copy of the document on arrival, and while waiting for their 
appointment, they were asked to read it and to reflect and comment on each parameter. 
There was no training or orientation. The completed document was used to structure the 
clinical consultation. In this consultation, each domain was mutually reviewed, discussed 
and a plan agreed. This was summarised into the dictated clinic letter addressed to the 
patient, in the first person, in the presence of the patient. A copy of this letter was sent to 
their general practitioner and other health care professionals as needed (the intention being 
that all aspects of the management were overt to the patient, no matter how complex, 
challenging or controversial). Hence, this clinic letter served as documentation of the care 
planning process, as the written care plan and as the communication of that plan to all other 
relevant heath care professionals. After the consultation, every patient was asked to 
complete a questionnaire to assess satisfaction, consultation alignment, productivity, 
engagement, patient–doctor relationship, and mutual learning and understanding. Each 
participating clinician was given a questionnaire to summarise their views at the end of the 
one-week pilot.        
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Fig. 4.1: Final structured care planning document 
 
Dear Patient 
Please look at your diabetes information overleaf. Please prepare yourself for your 
consultation with your nurse or doctor. Have a look at the various headings in the table 
and work out whether you think your position is good, borderline or is of concern.   If so 
think about what you would like to improve and what you might do to improve it.  Please 
show this letter and information to the doctor or nurse that you see and be sure that your 
concerns are discussed and dealt with in the consultation.  
My Diabetes Plan 
Where do I stand? Where do I want to be? How do I get there? 
My Lifestyle  (Diet, exercise, smoking) 
Good , Borderline , Of Concern    
My BMI  (Weight) 
Good , Borderline , Of Concern   
My Blood Pressure 
Good , Borderline , Of Concern   
My Cholesterol 
Good , Borderline , Of Concern   
My Circulation Risk 
Low, medium, High   
My Eyes 
Good , Borderline , Of Concern   
My Kidneys 
Good , Borderline , Of Concern   
My Feet 
Good , Borderline , Of Concern   
My HbA1C (sugar  control) 
Good , Borderline , Of Concern   
My Hypo risk (risk of low blood sugars) 
Low, medium, High   
My Medication 
Good , Borderline , Of Concern   
My Diabetes Knowhow 
Good , Borderline , Of Concern   
My Well-being 
Good , Borderline , Of Concern   
My Comments: 
 
 
 
 
 ⃝    Clinic staff to circle if unable to use forms in English. 
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Results 
Patients’ views of the care planning consultation 
We surveyed all 148 consecutive patients attending our routine diabetes clinics in one week, 
of whom 101 completed the form and responded to the questionnaire (Table 4.1), while 
others used the form, engaged in the process but did not return the associated 
questionnaire. Thus, we only captured the demographics of the 101 respondents (55 male, 
age 60±12 years, duration of diabetes 12±9 years, 67 on insulin, 3 new and 98 review 
patients; 63% were Caucasian, 14% Asian, 4% Afro Caribbean and 19% unknown ethnicity). 
Patients scored the process ‘good’ or ‘very good’ at around 80% for each question. Almost 
all patients (98% of those who replied to the final two questions) were happy with the 
behaviour and attitude of the doctor, and/or would be happy to see the same doctor again. 
Clinicians’ views of the care planning consultation 
All 12 doctors responded to the questionnaire (Table 4.2): six consultants, five middle 
grades, and one GP hospital practitioner. They generally rated the structured, patient-driven 
consultation process as ‘good’ or ‘very good’, reporting increased patient engagement, 
shared decision making, and better communication; they felt it was more time consuming 
though worthwhile. Crucially, this increased their insight into the patient’s needs. Another 
important point was that most clinicians felt that this was a learning opportunity that 
improved their consultation. 
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Table 4.1  
 
Outcome of a patient satisfaction questionnaire of the care planning consultation 
(undertaken as described) using the structured care planning document within a defined 
standardised process (n = 101 respondents of 148 surveyed with 8 questions against a 4 
point scale: poor; satisfactory; good; very good). 
 
 
Questions 
 
Good or  Very Good 
Of 101 respondents  
Do you feel the consultation covered your medical problems?  81 
Were your concerns and questions addressed?  76 
Did you receive a clear explanation of your medical care?  81 
Were you given a clear explanation of what will happen next?  79 
General opinion about the care planning process?  77 
How did you find the overall attitude and behaviour of the doctor?  82 
Would you be happy to see this Doctor again?  81 
 
 
  
 
94 
 
Table 4.2 
 
The outcome of a survey of clinician undertaking (as described) a standardised structured 
care planning consultation (n = 12 surveyed with 13 questions against a 4 point scale: 
definitely not; maybe not; yes maybe; yes definitely). 
 
 
Question Yes (N, %) 
(definitely or may be) 
Does the care planning document facilitate the consultation?    10 (83) 
Did you find patients were more engaged with the consultation?     10 (83) 
After the patient had done some reflection with the help of this 
document, do you feel that the document helped align the 
patient’s agenda and the clinician’s agenda?      
9 (75) 
Do you feel you had a better understanding of the patient's 
concerns?     
9 (75) 
Do you feel this document helped you to structure your 
consultation to address the concerns and needs of the patient?       
10 (83) 
Did the patient’s document enable you to do care planning and 
generate the clinic letter in a structured way?      
9 (75) 
Do you think your clinic care planning letter to the patient will 
enable the patient to recall and reflect on the consultation at a 
later date in a positive way?     
11 (92) 
Do you think it is appropriate to write to the patient cc GP with 
this sort of information (rather than write to the GP with or 
without cc patient)?     
9 (75) 
Does this type of consultation require more time than usual?     7 (58) 
Does dictation of a structured letter consume more time than 
usual?      
9 (75) 
Assuming more time was felt to be required - do you feel that it 
would be worth it?  
9 (75) 
Do you feel it is a good idea to incorporate this process into 
routine diabetes consultations?  
9 (75) 
It is hoped that the process is also a learning opportunity for the 
professional. As a reflective practitioner, did the process increase 
your insight into the patients’ needs and there by improve your 
own consultation skills?    
9 (75) 
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Discussion 
As a principle, it is important to understand the difference between a care plan and care 
planning (177). A care plan is a document. Care planning, however, is a process. The 
implementation of care planning into practice is a new experience for both patients and 
clinicians, and it is ill defined. With the shift to concordance models of care that respect and 
incorporate the patient’s views into day-to-day practice (183), the struggle is to know how 
to make the fundamental principles of patient centeredness, enablement and 
empowerment a reality (159). Care planning is a crucial tool that is intended to align the 
needs and agendas of patients and clinicians alike into a joint consultation, to facilitate 
meaningful, shared diabetes management planning, and in order to promote better care 
and outcomes. 
The risk, however, is that a care plan will be drawn up by a knowledgeable and trained 
professional ‘for’ a patient who lacks knowledge, information and an understanding of their 
diabetes or the process. To mitigate this risk, it is necessary for a patient to understand their 
diabetes and their role and rights within the intended process, and for the intended process 
to be well defined. Conventionally, it is considered that education is the means by which 
patients acquire this knowledge, and become more expert. Education aside, the biggest 
failure within current ways of working may be that patients do not have specific information 
about their own diabetes in order to make assessments or decisions and this has been 
evidenced, as has been the impact of information provision (184). In this process, we did not 
provide generic diabetes education to patients, nor any specific training on how to use the 
document or on how to engage in the process, and the document did not contain specific 
patient-level information. The contention was that within a structured framework of judging 
or assessing themselves, patients would be able to reflect on and express their own 
perceived position on various domains of diabetes care, however accurate or inaccurate, 
and that this could be used as a platform for a constructive dialogue. In relationship to that 
dialogue, a key challenge was the need to ensure that the consultation behaviours of 
clinicians were calibrated to the needs of the care planning process: to value and use the 
completed document; to be respectful and be receptive to the views expressed by patients 
in that document; to engage in a structured and systematic way in a formative dialogue in 
each domain outlined; to agree and not impose a plan of action; and to ensure the 
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documentation and communication of the agreed plan were in partnership with the patient. 
This did not require any major effort, but a short simple orientation – focusing on an 
awareness of their role and responsibilities in a patient-centric and patient-driven care 
process leaving them to adapt their personal style to facilitate such consultations. 
It was, however, useful for clinicians to be aware of notions of patient activation and the 
positive impact of motivational interviewing on self-management, psychological and 
glycaemic outcomes (185) although it can be influenced by participant and delivery factors 
of these types of motivational interventions (186). However such interventions may help 
them to engage their patients at a constructive level of partnership working, tailored to that 
individual. There is evidence that effective physician– patient communication results in 
better health outcomes (154), and short duration training in this context has been found to 
be as equally effective as long-term tariff training (187). Thus, this was not an extensive, 
taught process, but an expectation for modified or learned behaviour. All of this was done in 
less than 1 hour in one of our standing educational meetings, with about 1 hour of 
preceding awareness raising and orientating information provision by email. 
Thus, from what might have been a very difficult process, underpinned by a number of 
complex underlying principles, this translated into a simple mechanism – a simply structured 
systematic document based on a reflective model; completed by patients with no 
orientation or training (while waiting); encouraging patients to self-assess their diabetes 
(agnostic to their attitudes, aptitudes or knowledge); formulate a potential plan; be free and 
comfortable in expressing their concerns; setting an expectation that these will be 
respected and addressed; defining for clinicians the nature of that expectation; establishing 
a standardised process by which the transaction might be executed. 
The outcome was positive from both the patients’ and the clinicians’ perspectives. Clinicians 
had the perception of increased time allocation; however, this process has not had any 
effect on either the number of consultations/clinics or the 30 minute waiting time target 
and, since this pilot, the care planning process has been incorporated in all of our routine 
diabetes clinics without any additional time allocation. Evidence suggests that such 
consultations might not take more time, but rather, are more balanced and more focused 
(188), although others have suggested the potential of a negative impact (130). Thus, based 
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on the principles outlined, and from a patient and clinician perspective, we believe this to be 
the first published evaluation of the framework methodology for the implementation of a 
diabetes-specific care planning process, although in a controlled study others implemented 
a similar process to find positive outcomes in the content and structure of the resulting 
consultation (188). 
The principles and philosophies underpinning the ‘Year of Care’ project are common to 
those outlined here, and authors have published on the development of their process and 
qualitative analysis of the perceptions of patients and professionals, although we are not 
aware of quantitative outcomes. 
We conclude that worthwhile care planning can be introduced into specialist diabetes clinics 
with little effort or no expense. Based on the findings of this pilot study, we planned to 
conduct a large-scale, randomised controlled trial to examine in detail the effectiveness of a 
care planning tool that empower people by providing them with their individualised 
diabetes information, on the quality of care in diabetes and its related outcomes. 
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Chapter 5: Wolverhampton Interface Care, Knowledge 
Empowered Diabetes-The WICKED Project 
Based on the learning gained from the historic and current models of care delivery across 
UK, we have restructured our diabetes care delivery in a new model of integration in 
Wolverhampton called “Wolverhampton Interface Care-Knowledge Empowered Diabetes” 
(WICKED). So far, all the models of care delivery have incorporated one or the other facets 
of integration and have explored that facet well but we aimed to develop a model that can 
embrace all aspects of integration not only among the services but also integrate active, 
informed and empowered people within the service delivery model of care. This is an 
attempt to shift the focus from a service centred approach to a people centred approach of 
care delivery. In previous chapters it is discussed that all these models of care delivery were 
perhaps rolled out as a service development, hence the lack of evidence around their 
outcomes. Therefore, it is important that every model of care should have fundamental 
principles embedded in the delivery of care backed by a research framework to extract 
robust evidence in order to implement the benefits of such a model to the wider NHS 
community. Our model is based on eight fundamental principles discussed below.      
The principles of WICKED model 
That the model has Corporate Governance 
Clinical Governance is well defined in the new NHS, which imposes statutory duty on all 
healthcare organisations in the NHS to ensure quality improvement (189). Key components 
of clinical governance are well described (190, 191) as the mechanism to ensure improving 
quality in health care delivery as defined by the WHO. It is divided into four aspects of 
professional performance, resource used, risk management and patient satisfaction with 
the service provided (192). Most clinicians generally understand its attributes, and strive to 
achieve best quality of care.  
Yet within a fragmented NHS attempting to operate a complex care long term condition 
such as diabetes across variously commissioned internal boundaries without wider 
corporate governance (193), clinical governance often feels like a futile pursuit. In order to 
deliver effective clinical governance,  those accountable and responsible for any model of 
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health care delivery must consider the following aspects:  Organisational governance, so 
that the requirements of the model are formally agreed to be implemented within and, 
most especially, between relevant organisations; Structural Governance, so that the 
resources and infrastructure are in place and can be managed to deliver that which has 
been agreed to be delivered; Financial governance, so that funding is in place and properly 
managed and effectively utilised and,  perhaps of most vital importance, Data Governance 
without which there is no potential for informed decision making on the basis of evidence. 
That the model is Ethical and Principled 
In the UK it is an obligation of the NHS that every person has a right of health care 
regardless of geographical, social, cultural or ethnic boundaries. The core principles are well 
understood (118). They are embraced in the Tavistock Principles (194) of rights, balance, 
comprehensiveness, co-operation, improvement, safety and openness and extended to 
notions of effectiveness, appropriateness and rationing, in Justice for Health (118). 
That the model is actively User Centric 
It has almost become passé to claim that service delivery is patient or user centric, but all 
too often, this is a service centric notion of customer care. In service design terms, however, 
this feeds into the concepts of equality and equity of access (195), effective and appropriate 
care, risk driven care and the potential to impart benefit without causing harm. Thus it 
drives care in relationship to Need, and then requirement for capacity management and 
prioritisation (if rationing is too emotive a term). It changes the aspirational notions of 
integrated care to a practical out turn impacting at the patient and service interfaces and at 
the inter service boundary.  
Further, the model links in a somewhat more abstract or intangible way to concepts of 
patient empowerment, engagement and activation (196) and it means that these become 
necessary outcomes of the proposed model in their own right, without which the power 
dynamics cannot shift from compliance to concordance or from a hierarchical relationship 
to one of partnership, as now needs to be epitomised in modern concepts of care planning 
with a modern understanding of roles and responsibilities (140, 197). 
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That there is Equality and Equity in service Access, Process and 
Outcome 
Care cannot be provided to those who do not or cannot access it, and when they do access 
it the provision of care may be partial or incomplete in terms of process, and clinical 
outcomes cannot be delivered without process. The final delivery of good and appropriate 
outcomes requires further variation according to “Need” and the “potential to benefit”.  
Even then, the attainment of good outcomes may not be the governed and performance 
managed end point of effective access and process provision.   
Equality of “Access” to healthcare can be taken at face value at the level of geography, 
availability, acceptability, meaning an equal or fair opportunity to access a defined provision 
of care (110, 131) but it must also be about quality.  Equity in healthcare is the practical 
corollary of the relationship between “Access” and “Need” to provide the same services to 
people with equal need and varying ability to access it (Horizontal Equity) and different 
services to those in different, worsening or escalating health care need scenarios again with 
variable access constraints (Vertical Equity). Equity is the notion by which, for example, a 
person with diabetes and severe psychiatric illness would receive effective care to prevent 
end stage diabetes morbidity that an equal provision of funding, resource and services 
would simply not attain. Equality extends to equity when resources and services are flexed 
(and thus become unequal) to attain equal access, process and outcome. Thus the 
attainment and measurement of equity is complex and difficult to either execute or 
evaluate (198).  The huge geographical variations in delivery of diabetes care and in hard 
end point clinical outcomes across the UK despite national frameworks of structured and 
audited care delivery manifestly reflect the failure to execute equality and equity (26).  
That the model is Effective, Efficient and Appropriate by linkage to Risk 
and Modifiable Risk 
The concept of Need is diverse, and all too often the key driver, but it can be moderated and 
simplified by applying the principle of “capacity to benefit” (199) which in turn relates to 
concepts of risk and modifiable risk.  Interventions that can modify risk are amenable to 
analysis of related benefit and harm.  Whilst this involves a judgment of benefit, it can be 
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informed and justified on the basis of available quality clinical evidence and cost benefit 
analysis (118).    
Orientation and Integration at the Interface 
Orientation 
True user centricity drives model design away from service centricity.  A conventional 
service centric model is often depicted as being 2 tiers (primary and secondary care) or 
maybe 3 tiers (primary, intermediary, and secondary). In such models, the patient is often 
an invisible commodity. Their ownership is with organisations that have discrete boundaries 
and internal corporate, financial and clinical governance agendas which may become 
territorially and competitively counterproductive. Meanwhile, the worthiness of community 
care is relegated to notions of geography and organisational positioning (e.g. none acute), 
and the value of specialised care according to specific need is lost.  
In WICKED, the patient is depicted centrally, in the context of their friends and family, and 
set within their community. This provides a formal framework to contextualise the relevant 
needs of the patient and their community. Thus, Community Diabetes becomes that form of 
specialised care that meets the needs of people whose diabetes presents additional 
difficulty in their community context to a degree that they lose equity in diabetes health 
care and are thus disadvantaged. This may be because of social isolation, immobility, 
dependency, multi morbidity, dementia, psychiatric illness, end of life care needs or it may 
be in the context of work or schooling.  A crucial example of this is a community start-up of 
insulin therapy, which may simply be in an NHS environment out of a hospital but this 
geographical shift should not be taken anything more meaningful than just being more 
convenient. It would not however qualify as a community start of insulin within WICKED, 
which is about additional and significant risks imparted in their personal and community 
context such as social factors, the home environment, the setting within their family, 
dependency and care needs, work or school based problems not to mention attitude, 
aptitude, vision, dexterity, and hypoglycaemia risk.  The patient, with their various levels of 
complexity, interfaces with the NHS (and vice versa) in 2 blocks, primary care and specialist 
care (and this is not simply specialist diabetes services) and these 2 care blocks interface 
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with each other. These are not organisational boundaries, but relate to care needs being 
self-care in the context of their community, primary health care and specialised health care.  
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Integration 
Faced with growing demands, an ageing population and an increased prevalence of 
diabetes, fragmented service provision in the NHS will result in wasted resources and poor 
outcomes.  Accordingly there is a desire to move to integration of services to extract 
efficiency benefits (85). Although often discussed, the implementation of integrated care is 
still sporadic and often local to individual health economies and anecdotal. Added to this is 
the lack of evidence base to determine its effectiveness and sustainability in the wider NHS 
(200).  Various UK models of diabetes care have tested different components of integration, 
but there is little outcome data available (66, 69, 71, 73, 75, 201), largely because they 
relate to service redesign implemented without the research methodology needed to 
provide evidence. Not only may it be difficult to achieve but it remains poorly understood. 
For true integration, health organisations need to work together at various levels.   
• Macro-integration is the alignment of commissioning and service providers to deliver 
the healthcare needs of an entire population and, whilst it is considered effective, 
and has been successfully achieved in various USA HMO models in the USA (202-205) 
it seems almost impossible to implement it in the current NHS governance model.  
• Meso-integration is the inter or intra organisational delivery of health to particular 
groups or categories of patients, often encapsulated within care pathways (206-209)  
• Micro integration focuses care provision to individual patients (210, 211). 
Micro Integration, Model Integration and Integration at the Interface 
Understanding of patient interfaces is vital to develop a patient focused model of care and 
to integrate services according to the needs of the people. The figure below (Fig 5.1) 
highlights those interfaces that a person with diabetes will have in their daily life. These 
interfaces are unique for each individual depending on their social circumstances, care 
needs and disease specific needs. Therefore, these interfaces are fluid in nature, and can 
significantly change in proportion over a period of time and hence a model of care should be 
aware of these interfaces and tailor the delivery of care to meet the ever changing needs of 
the patients and their interfaces. 
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Fig. 5.1: Ideology of patient centric interface care  
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Whilst macro and meso integration are vital, it is at the point of micro integration, at the 
level of the patient, which failure of care manifests, is most readily measured and is so 
depressingly destructive. It may not be inter organisational integration that will address that 
failure. Thus, an obligation for services to integrate should not be confused with the need 
for the governance of a model of care to be integrated in order to identify those at various 
risks and drive care. To address that risk, the requirement may be for the responsible 
service to deliver more effectively (patient / service interface), for services to co-work, or for 
transfer of care provision between services (inter service interface). Indeed, integration may 
become counterproductive when its execution generates further potential for failure (e.g. 
failure to identify those at need, referral based systems that fail), or where accountability 
and responsibility becomes confused and as such these interfaces are known to be the most 
likely point of breakdown of effective care and communication (212). Complexities in 
integration extend even further, such that a patient on retinopathy, foot, renal, glycaemia 
and hypertension pathways may not receive effective inter care pathway integrated care.  
The model should thus be effective in delivering equity of access to appropriate and 
effective care through model driven patient centric integrated service provision, and, in this 
context, integration has a broad remit.  
Thus, in our model of care, the aspiration is for a commissioned framework, with both 
corporate governance and clinical governance, with clear ethical principles, based on user 
centricity (with activation, empowerment, and enablement), with an imperative to deliver 
equity of access to appropriate and effective care that through model driven patient centric 
integrated service to drive service provision.     
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The Structure of the WICKED model 
A model that covers the whole epidemiological base works on the basis of push and pull. It 
endeavours to “Push” people to self-care by promoting information, knowledge, 
empowerment and building confidence to promote shared decision making-a notion called 
patient activation. It “Pulls” people who are at higher risk identified by data governance and 
streamlined by risk stratification into a seamless integrated primary and specialist services 
framework to break clinical inertia-a notion called service activation.  
Patient Activation 
Although patient activation is a term that has been in use for last 2 decades, it is not clear 
what activate the patients. There is a wide spectrum of interventions from education to 
consultation to care planning and partnership working that can potentially activate patients.   
In the WICKED model, we used information provision as an intervention to activate the 
patients. We believe that all individuals have the capacity to learn from the information. 
When such information is provided in a simple yet structured format, it starts a thought 
process and urges people to explore further information. According to the theory of change, 
a person needs to be dissatisfied about a situation and should be able to visualise a better 
future, and combining with the first step taken towards change exceeds the resistance to 
change, the change happens (213). We believe that information provided in a structured 
way can act as a catalyst for dissatisfaction, and can provide an insight into how the future 
might look like. Furthermore, the encouragement to reflect and set personalised agenda to 
take first step towards the change can be the key. The current project is based on the 
hypothesis that information provision used as an intervention can activate people to change 
by completing their key care processes as a first step in their diabetes care delivery. In the 
next chapter, it is explained how this hypothesis of patient activation was tested in a large 
scale RCT. 
In the WICKED model, activated patients are supposed to self-care as well as informed and 
empowered patients will be able to set personalised goals and develop an individualised 
care plan by working in partnership with their healthcare professionals.  
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Other facets of patient activation include the provision of tailored education according to 
the needs of the patients based on actual or perceived benefits to the individuals rather 
than adapting a blanket approach to provide structured education to everybody that may 
not be the requirement of that very individual, and hence a waste of valuable resource. It is 
evident that the uptake of such structured programs is sub optimal across the country, 
despite being in place for over 10 years (26). 
Therefore, we believe that patient activation is a core component of the WICKED model that 
enables the concept of patient centricity and allows users to integrate at a level of service-
user interface that permits them to drive services according to individual needs, rather than 
in direction of service directed pathways.    
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Service Activation 
Service activation is a new term used as a part of the WICKED model of care. To understand 
the concept of service activation, it is important to provide a brief overview of patient’s 
journey through different care pathways in a standard NHS health economy. 
Most patients come into direct contact with their primary care physicians who are 
responsible for providing both acute and chronic disease management to the patients 
usually for a long period of time. Primary care clinicians manage most of conditions 
themselves and if further help is required, then the referrals are made to multiple providers 
of community and specialist care. For a person with diabetes, diagnosis is usually 
established by their GP except in the case of type 1 diabetes, which can present direct to 
hospital via Accident and Emergency (A&E) department in the form of a medical emergency 
called Diabetic Ketoacidosis (DKA). GPs manage the diabetes based on the NSF, QOF and 
standard nine key care processes up until the point when patients need specialist 
treatment, usually in the form of injectable therapies or complications related input. 
Community services such as podiatry also require referral from the GP to review people 
with diabetes related foot problems. Most of these pathways are referral dependent, and 
require a healthcare professional to trigger a pathway to let people access the services they 
need. 
Clinical inertia in diabetes is now well recognised, and is defined as “failure of healthcare 
providers to initiate or intensify therapy when indicated” (214). Significant delays in 
intensifying the treatment in people with diabetes results in poorer outcomes (215, 216).  
This inertia not only exists in primary care (217), but also in specialist services (218), as well 
as during hospitalisation (219, 220). It is a complex issue, with multiple factors contributing 
to it such as poor patient concordance and adherence to the treatment (221), healthcare 
system related barriers and impaired perception about responsibility among clinicians (222). 
One key enabler to overcome this issue of clinical inertia can be pan systems, data driven 
risk stratification of people based on their clinical parameters regardless of their care 
settings. Hence integrated co-working informed by effective data governance to overcome 
clinical inertia is a core principle of the service activation limb of the WICKED model of care.  
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In WICKED, we use referral free, data driven risk stratification to inform both primary and 
specialist care services to focus people who are at higher risk of diabetes outcomes to 
provide integrated services to meet the needs of those people. In this process, the 
Wolverhampton is divided into six clusters that comprise of a group of GP practices, their 
named consultant, named diabetes specialist nurse and an allocated prescribing advisor. By 
using the database, all people with higher clinical risks based on three parameters including 
HbA1C, BP and Cholesterol levels are identified virtually (Table 5.3). Lists of these people are 
forwarded to each GP practice, and their named diabetes consultant and DSN for review 
prior to arrange a face to face meeting of the team to discuss all those patients to devise an 
action plan. These meetings are arranged by mutual agreement between primary and 
specialist care team, and are attended by the practice nurse, lead GP and diabetes 
consultant and specialist nurse. All patients are virtually reviewed for their access 
constraints, risks, diabetes care processes and long term outcomes. This whole process is 
repeated after 6 months to monitor the progress and to continue with the action planning 
to target high risk people.     
This approach results in an interface care development, whereby primary and specialist 
services operated independently yet coming together as an overlap to create an interface 
for the high risk patients to be managed in a timely and adequate way hence addressing 
failures of referral pathways as well as issues around clinical inertia (Fig 1.5). This is what we 
call service activation across NHS bounds. We believe that it is very hard to deliver a 
standardised service to every person with diabetes, and principles of equity and equality in 
care should be observed when trying to utilise resources in a most efficient way. 
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Table 5.1: Data driven risk categorisation of the whole population including failed processes.  
Parameter 
 
Any result 
n =17323 
 
15 months Value (Any) Higher risk levels Failed Outcome 
Clinical Risk 
Tier 1 
Failed Outcome 
Clinical Risk 
Tier 2 
HbA1c 16736 (96%) 15598 (90%) 7.6 ± 1.65 % ≥7.5, 6553 (38%) 
≥8.5, 3701, (21%) 
≥9.0, 2665, (15%) 
Any of 
 
HbA1c ≥ 8.5, 
SBP ≥ 160, 
Chol ≥ 6 
 
4807 (28%) 
 
Any of 
 
HbA1c ≥ 9, 
SBP ≥ 160, 
Chol ≥ 6 
 
3777 (22%) 
 
SBP 16446 (95%) 15750 (91%) 133 ± 15.3 mmHg ≥140, 4249 (25%) 
≥160, 864 (5%) 
Cholesterol 16670 (96%) 15322 (88%) 3.8 ± 1.4 mmol/l ≥5.0, 2777 (16%) 
≥6.0, 1020, (6%) 
Smoking status * 15848 (91%) 15848 (91%) Never, 9086 (53%) Current, 2143 (12%) 
Vascular status * 17323 (100%) 17323 (100%) Primary 13319 (77%), Secondary, 4004 (23%) 
1O CHD Risk Score* 12094 (91%) 12094 (91%) 14 ± 8 % over 10 years ≥15%, 5019 (29%) 
≥30%, 582 (3%) 
Any Macrovascular 1O CHD Risk Score >=30% or Secondary 4586 (27%) 1382 (29%) 1125 (30%) 
Retinopathy 16197 (93%) 14321 (83%) None, 9701 (56%) Any retinopathy, 6496 (38%) 
Vision threatening, 1712 (10%) 
2332 (49%) 
802 (17%) 
1835 (49%) 
633 (17%) 
Creatinine 16795 (97%) 15762 (91%) 90 ± 47 umol/l ≥120, 1743 (10%) 
≥150, 735 (4%) 
552 (11%) 
264 (6%) 
457 (12%) 
229 (6%) 
E GFR* 16795 (97%) 16795 (97%) 77 ± 23 ml/min ≤60, 3809 (22%) 
≤30, 466 (3%) 
1035 (25%) 
177 (4%) 
818 (22%) 
160 (4%) 
ACR 16187 (93%) 13938 (81%) 10.0 ± 46.0 ug /umol ≥10, 1047 (6%) 
≥30, 899 (5%) 
801 (16%) 
399 (8%) 
679 (18%) 
343 (9%) 
Any Renal Creatinine > 120 or e-GFR ≤60 or ACR≥30 4206 (24%) 1235 (26%) 989 (26%) 
Any Retinal or Renal As above + any Retinopathy 8793 (51%) 2862 (60%) 2250 (60%) 
Any Vascular As above + any Macrovascular 10463 (60%) 3272 (68%) 2594 (69%) 
Foot 15105 (87%) 11965 (69%) Low risk, 6724 (39%) High risk, 3123 (18%) 873 (18%) 704 (19%) 
BMI 14558 (84%) 14266 (82%) 30.8+-6.3 kg/m2 >30, 7255 (42%) 
>40, 1201 (7%) 
  
 
Failed 
Access & Process 
  
5506 (32%) 
 Either 8594 (50%) 
Access, 3787 (22%) 
Risk, 3088 (18%) 
Both, 1719 (10%) 
 
Either 7927 (46%) 
Access, 4150 (24%) 
Risk, 2421 (14%) 
Both 1356 (8%) 
 
 
111 
 
Project Plan 
Aims and Objectives 
1. To confirm that full data acquisition from multiple data sources into a centralised 
diabetes register can be attained and validated regularly within a fragmented 
English NHS. 
2. To establish that delivery of a structured report reflecting process and key 
outcomes in diabetes individualised to each patient is possible despite the above 
barriers. 
3. To determine whether people with diabetes can utilise such a structured report 
based on key diabetes parameters relating to diabetes care processes in a way 
which drives objective improvement in their processes completion rate. 
PICO of Project 
Population 
All people with diabetes over the age of 18, both male and female, with all types of diabetes 
diagnosis, and registered in Wolverhampton Clinical Commissioning Group (WCCG) area, 
were recruited in the trial.  
Intervention 
Delivery of an individualised structured diabetes care process and outcomes report in the 
form of a printed A4 size booklet via postal mail to the population described above. The 
active group will receive this booklet at 0, 3 and 6 months intervals and will be compared 
against a control group that will receive this document once at 3 month. 
Comparison 
At 3 months’ time point, active group who received one mailing will be compared against a 
control group with no mailing. At 12 months active group who received multiple mailings 
(n=3) will be compared against a control group who has only received one mailing. 
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Outcomes 
Primary 
1. To determine that such a structured and personalised information booklet can be 
established and mail delivered to a large population covering the whole 
epidemiological base in a local health economy.  
2. To observe any change in the completion rates of nine key care processes in diabetes 
reflective of patient activation induced by the intervention. 
Secondary 
1. To determine whether people with diabetes like to receive such information and can 
utilise it to activate themselves to self-care.  
 
Study Registration: 
The study was registered in the UK national research database (UK CRN ref: DRN 795, 
available at http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=14324) and US 
clinical trials database (Clinical Trials Registration: NCT02200965).  
 
Funding: 
British Medical Association (BMA) Joan Dawkins Grant 2012 partly funded this project but 
has no role in either execution of the project or writing of this thesis. 
Ethical Approval: 
Ethical permission was obtained from NHS Health Research Authority, NRES Committee 
North East-York; REC Ref 13/NE/0052; IRAS project ID 117977 (See Appendix 3). Further 
clarification was obtained from National Information Governance Board as per REC 
recommendations. 
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Research Methodology 
Establishment of the database 
Establishment and validation of an electronic district diabetes register has been discussed in 
detail in Chapter 3.  
To instigate this project, a functional and up to date database was of the utmost 
importance. Before the project could be executed, we established both clinical and 
demographic feeds into the database that was getting updated as a complete dataset at 
least once a month. Our multisource feed included data from the primary care data 
warehouse, retinal screening programme, hospital Patient Administration System (PAS), 
local pathology lab and direct data entry from our paperless inpatient and outpatient 
diabetes specialist services. This database was subject to a rolling process of revalidation 
against hospital coding system and against NSTS on a quarterly basis, to ensure the accuracy 
of the information that is consistently found to be more than 95% accurate.  Patient 
movements in and out of the area, updating new diagnosis and deceased patient status 
were a few challenges that were faced in the day to day maintenance of this database. All 
people who were alive on 30/10/2013 were downloaded and included as a baseline 
population for the project. 
Development of Project Intervention 
This project is based on the provision of information about nine care processes directly to 
people with diabetes. To execute this information provision we needed to develop a highly 
structured yet simple tool that could not only deliver the desired information to the people 
in an understandable way, but could also encourage them to take the necessary action to 
make the required change where applicable. To develop this tool, a research focus group 
was established that included 4 lay people with diabetes, representing 2 local public 
diabetes networks, a local diabetes structured education programme trainer (EXPERT 
Program), 3 clinicians (2 GPs and 1 hospital consultant) and a graphic designer from the 
medical illustrations department of a local hospital. 
During the first meeting, the agenda was to develop a tool that can serve the purpose of 
information delivery to the patients. After agreeing on the basic domains to be included in 
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the tool, the task to develop a document to reflect those domains was allocated to the 
author. A questionnaire with guidance notes and reflective plans was developed, and 
subject to discussion in the second meeting. The agenda of this meeting was to discuss the 
purpose, comprehension, utility, centricity, value, relation to diabetes management, and 
novelty of this report. The layout, design and colour scheme were also discussed. We 
further discussed the development of a patient questionnaire that could assess all the above 
mentioned aspects of this report.   
After the second meeting, a document was designed with the help of local medical 
illustrations department. A detailed structured questionnaire consisting of 16 questions was 
designed to inquire about all above mentioned domains, and was given to the focus group 
for review by e-mail. After seeking approval from the group, this document was given to 50 
consecutive patients attending the diabetes centre clinic over a period of 2 days. The 
structured questionnaire was used to receive their anonymised feedback.  The results of this 
pilot are available in the results section of this chapter. 
The outcomes of this pilot were presented to the research focus group and based on the 
outcomes, final amendments were made to develop the final booklet that was edited 
accordingly and was resent to all members of the group to seek final approval. After these 3 
cycles of development, a final project intervention document was created (See appendix 1).  
Project Intervention Tool “My Diabetes, My Information, My Plan” 
booklet 
The project intervention tool is size A4 booklet named “My Diabetes, My Information, My 
Plan” (Attached as appendix I). This booklet complies with standard NHS written 
information provision guidelines. It is printed in a yellow colour with dark black text that has 
the most visibility for people with impaired vision and colour blindness. All text meets 
minimum requirements of readability in terms of font size, and scored 6 on Flesch-Kincaid 
Grade level readability test. This document is based on the fundamental principles of adult 
model of learning “Do, Review, Learn, Apply”, which maintain that all adults can learn from 
the information provided to them in an easy and understandable way, and once they are 
empowered by the knowledge of this information, they have the ability to reflect and act so 
as to achieve better self-care and diabetes outcomes.    
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In this document, the first page introduces the document to the recipient. It navigates the 
person to read the detailed guidance of how to use this document and further available 
guidance on the back page. It also allows them to ring on a phone number in case they have 
any questions around the utility of this document or to inform us if there is any change in 
their circumstances.  
The middle 2 pages of this booklet contain all the information. Page 2 is called “My Diabetes 
Information”. This page has individualised information mapped against nine key care 
processes in diabetes with a brief one word clinical comment; Good, Borderline or Of 
Concern, so as to provide the reader with some help to make sense of this information. Only 
information of preceding 15 months (in line with QOF guidance at that time) was included in 
this page, and if any information was older than this or was not completed previously, it was 
marked as “Needs Doing”, to prompt patients to think about getting that test or measure 
done as soon as was practical for them.  
Page 3 is called “My Plan”. This page is mapped against all the information given on page 2 
and has 3 columns. The first column, “Where am I”, encourages patients to write about their 
thoughts after knowing about their information related to their diabetes. The second 
column, “Where I want to be”, prompts patients to reflect on their own status of diabetes 
care and to set a personalised goal to achieve for their diabetes. The last column, “How I will 
get there”, prompts them to make an action plan to achieve those targets that are set by 
them and to work out ways and means of how to achieve them. As these are patient’s own 
targets, we presume that people will make an individualised plan to achieve these targets, 
and wherever they feel that help from healthcare professionals is required, they will seek 
this help appropriately, as explained in the guidance notes on page 4. This tool can also 
inform carers and significant others of the diabetes status of the patients, since they 
sometime have a major responsibility to manage the diabetes of their loved ones or people 
under their care, and hence may activate the patient’s environment by activating family, 
friends and community.  
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Cluster Randomisation Process 
In 2010, Wolverhampton was ranked as the 20th most deprived of 326 English local 
authorities according to the English Indices of Multiple Deprivation (IMD) (223). It has a total 
population of around 265,000, of which nearly 17,000 people have diabetes. It is divided 
into 3 geographical regions within WCCG, and each region is divided into 3 subsectors to 
make 9 health subsectors of varying sizes and demographic makeup. The subsectors, and 
thus clients belonging to primary care practices within each of them, were cluster 
randomised by sub sector into 2 groups intended to be matched for age, gender, ethnicity, 
type of diabetes and baseline FPS, utilising pilot processes based on information gathered 
over the preceding 15 months. This meant that all clients belonging to any individual 
primary care practice and all practices within these individual subsector clusters were 
randomised in blocks, so that no practice had a mixture of mailed or non-mailed individuals, 
thus minimising any impact of care-providing professionals or practice specific process on 
the outcomes. Sub-sectors were placed in descending order of size, and were then paired 
with the nearest sub-sector according to size. The top two subsectors were allocated to 
active or control group by the toss of the coin, and each pair was then randomly allocated to 
either active intervention group or the non-recipient control group, thus creating cluster-
randomised practices (and their patients) accordingly. The last subsector was included in the 
active group to increase the sample size as we believed that this intervention will be of 
benefit, and we wanted a maximum number of people to receive that benefit. After the 
randomisation process, baseline data was further cross validated for patient movements 
and death status excluding another 105 patients from the baseline group (both active and 
control groups). All the people alive and in the area on 30/11/2013 were finally recruited in 
the study (Fig 5.2).  
 According to the study protocol, both groups should have been matched in their baseline 
FPS. Despite this cluster randomisation process, by hap chance, there was a mismatch in the 
baseline (pre-intervention) level of the key intended outcome variable, the full 9 parameter 
Failed Process Score (FPS), with a significantly better FPS in the intervention group. This was 
thus moderated by the removal of the 3 lowest scoring primary care practices from the non-
intervention group accounting for 1,871 control subjects so that the 2 groups were fully 
matched for all relevant variables at baseline prior to the intervention. Subsequently, after 
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randomisation and the mailing intervention, a further 263 patients had died or moved away 
by the 3 month analysis point and they were also excluded, leaving a final cohort of 14,559 
with 8374 (57%) in the active group versus 6185 (43%) controls at 3 month analysis point 
(Table 5.2).   
The 2 groups were allocated to either receive the document, which was an active 
intervention, or not. The document was mailed within the same week to the active group. 
Updated data were re-examined at 3 and then 12 months after this randomisation and 
intervention.  The core analysis related to the 9 key diabetes processes that inform UK NHS 
diabetes health care delivery – HbA1c, BMI, blood pressure, urine ACR, serum creatinine, 
serum cholesterol, recorded smoking status, digital retinal photography and foot 
examination. Each item was scored as 1 if missing and 0 if completed within a 15 month 
period and each individual thus had a summative score calculated to assess the accrued 
process failure – the Failed Process Score (FPS). This ranged between 0 - 9 equating to a 
spectrum from complete process attainment (FPS =0) to complete process failure (FPS =9). It 
is this parameter and its derivatives that were subject to analysis.  Data were analysed on 
SPSS version 22 with statistical tests taken as significant at p<0.05. The significance of 
difference between means was tested by Student’s T test, of differences between 
proportions by the Chi square test. Binary logistic regression analysis to derived likelihood 
ratios adjusted for relevant factors was carried out with the help of Prof Alan Nevill (Editor 
in Chief JSS, University of Wolverhampton, Faculty of Education, Health and Wellbeing) and 
discussed with Nick Parson (Statistician from University of Warwick).  
  
 
118 
 
This is a pragmatic, real life trial conducted on a large population base across bounds of NHS 
within a local health economy and it has been carried out with the best possible 
methodological rigour. For a trial of this magnitude and nature, there can be potential 
limitations or weaknesses in the trial design that need to be looked at in the given context.  
We used a process of cluster randomisation of the patients by their GP practices. 
Wolverhampton is a large geographical area that is divided into 3 sectors, with each sector 
being further subdivided into 3 sub sectors for the provision of healthcare by WCCG. As is 
the case with any other geographical location, it includes areas of higher and lower 
deprivation, a mixture of small and large size practices, variable availability of services 
within each practice and other population demographics that tend to vary from one part of 
the city to the other. The purpose of randomisation in a trial is to remove bias. In this type 
of pragmatic design, we need to be aware not only of demographic geographic variations, 
but also keep in mind that motivation, practice size and the structure of individual GP 
practices can influence the outcomes significantly. One of the markers that can be used for 
randomisation is the deprivation score. As deprivation score follows the patients and not GP 
practices and patients are free to register with any practice in any part of the city. We 
cannot calculate the deprivation index of the GP practices and hence cannot use this as an 
index for randomisation. Similarly individual patient randomisation is not desired in this 
study design, and we cannot afford to have a small number of patients in the same GP 
practice that are in the active group and others in control group. This will result in 
contamination and clinician’s bias. Therefore, we used the cluster size order to list all 9 
subsectors, and then paired them to the next sub sector for the cluster randomisation of the 
GP practices and hence their patients that created 2 equal size groups that will have a 
complete mix of GP practices and their patients without any issues around demographics or 
GP practice quality biases. In order to ensure that our randomisation process was effective, 
we compared all the demographic and care process parameters of the two groups and 
despite ensuring randomisation, we ended up with a very small differences between two 
groups that was a matter of pure chance, due to unknown or un identifiable reasons. As FPS 
was the main indicator to evaluate our intervention, the difference of FPS between the 
groups was moderated by the a-priori removal of 3 worst FPS practices from the control 
group according to study protocol. 
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Fig. 5.2: Flow chart of Cluster Randomisation Process 
 
 
 
 
 
 
  
Nine Sectors arranged in descending size order shown as numbers of patients in each sector 
 
No 3178  
 2201 Yes 
 2112 Yes 
No 1965  
No 1699  
 1636 Yes 
 1468 Yes 
No 1246  
 1030 Yes 
 
  
All GP practices in Wolverhampton n=51 
Divided into 3 regions  
Each region divided into 3 sectors 
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Control Group 
N=8056 
  
Active Group 
N=8374 
  
Further validation process excluded 105 
people from the database 
  
A-priori matching of baseline FPS score 
showed a baseline mismatch  
  
3 worse FPS score practices from the 
control groups were removed n=1871 
  
Final Control 
Group 
N=6185 
  
Final Active Group 
N=8374 
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Table 5.2 
The baseline characteristics of the 2 groups after a-priori matching based on FPS score.  
 Whole 
group 
Not mailed 
Control 
group 
Mailed 
Active 
group 
p value 
     
Group size 14559 6185 (43%) 8374 (57%)  
     
 Demographics 
     
Age years 64.0 ± 14.6 63.8 ± 14.6 64.1 ± 14.6 ns 
Gender (male) 7960 (55%) 3425 (55%) 4535 (54%) ns 
Ethnicity (Caucasian) 10124 (70%) 4351 (70%) 5773 (69%) ns 
Type of diabetes (type 2) 13412 (94%) 5688 (93%) 7724 (94%) ns 
Duration of diabetes (years) 10.5 ± 8.6 10.5 ± 8.7 10.5 ± 8.4 ns 
Deprivation score 35.5 ± 16.1 35.8 ± 16.6 35.2 ± 15.8 p<0.05 
     
 Process measures (n= 9) 
Showing process attainment and outcome 
     
Failed Process Score 1.74 ± 1.84 1.77 ± 1.88 1.73 ± 1.82 ns 
Failed Process Score category 
(Good) 
8336 (57%) 3526 (57%) 4810 (57%) ns 
     
HbA1c 
Outcome (% glycated) 
12522 (86%) 
7.8 ± 1.7 
5387 (87%) 
7.8 ± 1.7 
7135 (85%) 
7.8 ± 1.7 
 
ns 
Retinal status   
Outcome (no retinopathy) 
12000 (82%) 
6986 (58%) 
5087 (82%) 
2964 (58%) 
6913 (82%) 
4022 (58%) 
 
ns 
Urine ACR 
Outcome (umol / mmol) 
10100 (70%) 
9.0 ± 39.3 
4309 (70%) 
9.1 ± 44.6 
5791 (69%) 
8.9 ± 34.8 
 
ns 
Serum Creatinine  
Outcome(umol/l) 
12696 (87%) 
88.6 ± 44.3 
5373 (87%) 
89.1 ± 46.3 
7323 (87%) 
88.3 ± 42.3 
 
ns 
Foot status 
Outcome (low risk) 
10629 (73%) 
6091 (57%) 
4508 (73%) 
2586 (57%) 
6121 (73%) 
3505 (57%) 
 
ns 
Smoking status 
Outcome (non-smoker) 
11664 (80%) 
9935 (85%) 
4836 (78%) 
4074 (84%) 
6828 (82%) 
5861 (86%) 
 
p<0.05 
Systolic Blood Pressure  
Outcome (mmHg) 
12946 (89%) 
134 ± 16 
5459 (88%) 
133 ± 16 
7487 (89%) 
135 ± 16 
 
p<0.001 
Serum Cholesterol 
Outcome (mmol / l) 
12043 (83%) 
4.4 ± 1.1 
5151 (83%) 
4.3 ± 1.1 
6892 (82%) 
4.4 ± 1.1 
 
p<0.01 
Body Mass Index 
Outcome (kg/m2) 
11027 (76%) 
31.0 ± 6.3 
4620 (75%) 
31.0 ± 6.2 
6407 (77%) 
30.9 ± 6.3 
 
ns 
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Extension of the intervention to both arms at 3 months 
At the end of 3 months, all people in the control group also received the booklet for the first 
and only time, and people in the active group received the booklet for the second time. The 
active group received the third and final mailings at the end of 6 months, and both groups 
were followed up for 12 months in total (Fig 5.3). We continue to capture the data on a 
monthly basis as our routine data upload, but it was only analysed at 3 and 12 months 
intervals. A complete log of all failed deliveries returned back to the department and all 
phone calls received were kept for the record maintenance, but was not analysed, as it was 
less than 1% and unlikely to be of any meaningful significance, and thus, beyond the remit 
of the project. Therefore, the final analysis will look at a comparison of multiple mailings 
(n=3, Active group) vs. single mailing (Control group) at 12 months of first intervention. 
At the end of 12 months, a further 603 people deceased or moved away, resulting in 866 
people in total who were lost to follow up (Deceased=453, Moved away=378 and not 
traceable=35), leaving a final cohort of 13,956 people that completed 12 months of the trial.      
In an ideal world, we wanted to keep our control group for the whole 12 months duration of 
the intervention but due to governance issues with the WCCG as this intervention was 
supposed to benefit people, it was agreed that this intervention would be delivered to all 
people with diabetes in Wolverhampton within 3 months of the initiation of the project, and 
therefore we had to extend the intervention to control arm after 3 months. At this point, 
the data analysis was performed to compare the impact of mailing versus non mailing, but 
as the active group at baseline received 3 mailings in total, as compared to the control 
group that only received one mailing, the 12 months analysis will show the impact of one 
mailing versus multiple mailings between the two groups.    
  
  
 
123 
 
Fig. 5.3: Timeline of Open Label Extension Process 
 
Active group 
Booklet mailed                  Booklet Mailed                       Booklet Mailed  
Baseline                              3 Months                               6 Months                             12 Months 
  
 Data Collected                  Data Collected                                                                    Data Collected
     
No Intervention                 Booklet Mailed  
Control group 
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Power Calculation 
Power calculations were not performed at the beginning of the trial, for several reasons. 
However a retrospective power calculation has been performed. 
Power calculation is usually performed to determine the sample size of a study that is likely 
to detect the effect of intervention in a study. One of the main reasons for power 
calculation is to avoid type 2 statistical errors or false negatives. To calculate the power of a 
study, one need to know the effect size, sample size and alpha significance criterion. This is 
usually based on the results of a previous pilot project to determine an adequate sample 
size for the main study. In principle, power calculation is helpful when one is required to 
select a sample from an epidemiological population base.  
This project involved recruiting the whole epidemiological base and hence no sample was 
taken out of this baseline population within a local health economy. There is no known 
clinical trial or pilot study that can be used to determine either the effect size or sample size. 
Although a pilot study could have been performed prior to this project, it was not done 
because the intervention was found to be easily implementable to the whole population 
from the outset of this project, without incurring any unusual financial cost, time constraints 
and without putting any patients at risk. However, in retrospect, if we presume that after 
doing a power calculation, given sample size would have been smaller than this, then the 
present project would have been adequately powered. On the other hand, even if a sample 
size of this magnitude is not adequately powered, then the recruitment for the present 
study could not have been extended outside the local health economy bounds. As this 
project involves a unique database use to execute the project and to our knowledge no 
health economy in England and Wales has such a database it was practically impossible for 
the researcher of this study to expand sample size to neighbouring health economies. One 
may argue that the entire diabetes population is larger than the single health economy and 
hence this can still be looked at as a sample of the diabetes population as a whole, 
unfortunately, this was the largest sample that we could recruit in this study. Therefore, in 
my view, power calculation may not be relevant to this study and if anyone wishes to re-
perform this type of study in the future this project may serve as a pilot project to perform 
power calculation for such studies.    
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A further reason of not performing power calculation is that in this study we used a novel 
measure (FPS) to assess the impact of our intervention. This tool is not used or validated in 
any other studies, and there are no estimates of how much difference should we assume to 
set significance. There is much evidence to suggest that people who do not complete their 
care processes will have poorer outcomes in diabetes, yet a Failed Process Score to assess 
patient activation in self-care has never been tested before. Therefore, it was not possible 
to calculate the power of the study without any guide to estimate the magnitude of change 
to expect as a result of this intervention. However, if we perform retrospective power 
calculations to detect a 3% difference in FPS at alpha= 0.05 and Power= 0.8, the sample size 
required will be 3477 people in each arm, and thus, our study is proved to be adequately 
powered. 
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Patient satisfaction Survey 
To evaluate the impact of this tool qualitatively, we used a patient satisfaction 
questionnaire, containing 14 questions that were derived from the questionnaire that we 
used in our pilot project in process of developing our project intervention tool “My 
Diabetes, My Information, My Plan”. All the questions were re-evaluated by our research 
focus group, and the final questionnaire was designed by our medical illustration 
department in the form of 2 sided A4 sheet (See appendix 2).  We did not use any standard 
validated diabetes questionnaire, as there was no such questionnaire available to assess the 
usefulness of our tool. To develop a validated questionnaire for this purpose is perhaps a 
project in its own rights, and hence deemed beyond the remit of this project.   
The final questionnaire contained an introduction of the questionnaire and its relation to 
the evaluation of previously sent booklet to the patients on the front page. The second page 
had all 14 questions with a four scale answers to the most questions that include; “Yes 
definitely”, “Yes May be”, No May be and No definitely to allow people to express their 
thoughts about various domains of the booklet. Only one answer that was about the 
frequency of this booklet was divided into “Once a year”, “Twice a year” and “No I don’t 
want to have this information”.  
From the active group at baseline (n=8725) all people under the age of 75 were selected for 
this survey. From this cohort of people, 1000 were randomly selected for the survey by 
using MS Excel 2011 random number generation process. Sample size of 1000 was decided 
randomly. All people were mailed the questionnaire in the same week with a self-addressed 
reply envelop enclosed. All replies were collected and the questionnaire was re mailed to 
those who did not respond after 2 weeks. At the end of 4 weeks, the reply collection process 
was stopped and the survey was closed. 
At this stage, we had the FPS outcomes at 3 months post active intervention and we 
hypothesized that people with low process attainment were less active in self-care and 
hence FPS can be used as a marker of patient activation. After receiving the response of the 
survey, the group was divided into “responders and “non-responders” and we hypothesized 
that people who did not respond to the questionnaire were less active in their diabetes care 
and hence response rate to the questionnaire can be used as a second marker of patient 
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activation. By using these 2 markers of patient activation, we compared the FPS score, 
clinical risks and hard endpoint outcomes between responders and non-responders of the 
survey to test the hypothesis that less active people are likely to be at higher risk to develop 
diabetes complications. 
Using SPSS version 22, data were then analysed using the Student t-test or the Chi square 
test for the difference between means and proportions respectively with statistical 
significance taken at p<0.05.   
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Results 
The results of the data validation process, assessment of patient access pilot and care 
planning in diabetes clinics pilot have been included in their corresponding chapters. This 
section presents the results of user acceptability pilot, 3 months outcomes of project 
intervention comparing the active and control group with one versus no mailing contact, 6 
months patient satisfaction survey and 12 months analysis of project intervention with one 
mailing contact to the control group and 3 mailings contact to the active group. 
User Acceptability Pilot 
Of 50 patients, 37 responded (14 females, age 59±12 years, 7 type 1 diabetes, 23 on insulin, 
29 Caucasians). More than 80 % positively reported this document to be understandable, 
informative and helpful, and it promoted being in control / charge of the diabetes. 90% had 
never had such information before; they wanted it again, and said they would use it in 
consultation with professionals. 91% people resolved to use this information to take better 
care for their diabetes. Detailed results against each question are shown in the table 5.3. 
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Table 5.3 
Pilot user acceptability survey outcomes (n=37 out of 50). 
Questions Yes definitely or 
Yes to some extent (%) 
Did you understand the purpose of this document and what it is meant to be used for? 92% 
Were the contents of the report easy to read and understand and do they make sense to you? 92% 
Was the information useful? 89% 
Did this information give you more knowledge about your diabetes? 89% 
Did this information help you to understand your diabetes better? 89% 
Would this information help you to improve your diabetes? 86% 
Would this information help you make changes in your diabetes? 78% 
Will this information help you be more confident about your diabetes? 81% 
Would this information help you feel more in charge or control of your diabetes? 78% 
Would you take this information with you to your next diabetes appointment with a doctor or a nurse? 86% 
Did you think this information will help in your next visit of diabetes review with a doctor or a nurse? 84% 
Have you ever received information like this about your diabetes in the past? 76% (Never) 
Would you like to receive information like this in the future? 84% 
How often would you like to have this report with this sort of information about your diabetes? 81% (once/twice a year) 
Overall, do you think it is a good idea for people with diabetes to have this sort of report? 92% 
Overall, do you think people with diabetes will use this information to take better care of them? 84% 
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3 months outcomes comparing Mailed (Active) vs. Non-Mailed (Control) 
Groups 
The groups were well matched on all a-priori demographic factors, although, post hoc, there 
were very minor differences in the measure of deprivation, smoking status outcome, 
systolic blood pressure, and serum cholesterol (Table 5.2). 
At baseline, there was no significant difference in the Failed Process Score (FPS) whether 
measured as the numerical mean, the distribution in all 10 numerical categories (FPS 0 to 9), 
or the proportion with good attainment (GA, FPS ≤ 1) (Table 5.2). 
At 3 months, the FPS score, the change in FPS score, and an improvement in FPS ≥1 were all 
significantly better in those mailed vs. controls (Table 5.4, Figure 5.4). At 3 months the 
association with GA categorisation was 74% in the mailed group versus 71% in controls (χ2 
=10.0, p<0.05).  There was no impact of mailing in those with preceding GA (χ2 = 1.05, ns) (in 
other words the retention of GA status), nor on the proportion deteriorating from GA to 
poorer attainment (PA), (mailed 10.0% vs. control 9.3%, χ2 =1.0, ns).  However, the impact of 
mailing on the attainment of GA in those with preceding PA was significant with the shift 
from PA (FPS ≥2) to GA (FPS ≤1) being greater in those who had received the document.  
Examining the difference in percentage attainment of the GA category at 3 months for the 
mailed group versus control by individual FPS score categories (0 through to 9, 10 
categories) showed the differential percentage attainment with mailing to be positive in 
every category but with major changes in magnitude with a worsening baseline position 
(0=0.2%, 1=1.3%, 2=1.1%, 3=3.2%, 4=4.7%, 5=5.3%, 6=7.6%, 7=6.0%, 8=11.7% and 9=10% 
respectively, overall χ2  = 10.0, p<0.05) although the numbers in the lower attainment 
categories were relatively small. The change in FPS at 3 months was recoded into 
deterioration, no change or improvement (2924 (20%), 5356 (37%) and 6279 (43%), (Figure 
5.4) and, equating this to GA or PA categorisation attainment at 3 months showed 
significant differences (χ2 = 10.0, p<0.05).  With mailing, those with no change in FPS score 
were more likely to retain their GA status (82% vs. 80%, χ2 = 5.6, p<0.02), those who 
improved FPS score were more likely to attain GA status (84% vs. 82%, χ2 = 5.6, p<0.02) but 
those who deteriorated in FPS score were not affected by the mailing in their final 
attainment category. 
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Binary logistic regression analysis was used to compare the relative effect of mailing 
compared to non-mailing whilst taking into account all demographic factors and the 
baseline FPS (Table 5.2).  The relative likelihood, the odd ratio, of showing an improvement 
in FPS by ≥1 with mailing was 10% (p<0.05) with baseline FPS (p<0.001), age (p<0.01), 
deprivation score (p<0.01) and duration of diabetes (p<0.01) as significant co-variables; it 
was 14% (p<0.01) for the 3 month GA category (whether retention or attainment) with 
baseline FPS (p<0.001), age (p<0.05), and gender (p<0.05) significant co-variables, but was 
of greater magnitude at 18% (p<0.01) for attaining GA by moving from baseline PA with 
baseline FPS (p<0.001), age (p<0.05) and type of diabetes (p<0.01) significant co-variables. 
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Table 5.4 
The effect of receiving the personalised information booklet on 3 month diabetes process 
outcomes measured as the Failed Process Score (FPS, 0 = maximal attainment, 9 = complete 
failure of attainment).  Good attainment, FPS ≤1; poorer attainment, FPS ≥2; OR = Odds 
ratio.   
Variable Not Mailed vs. Mailed  
 n=6072 vs. n=8224  
FPS at 3 months 1.35 ± 1.97 vs. 1.25 ± 1.87 p<0.01 
Change in FPS from baseline 0.42 ± 1.49 vs. 0.48 ± 1.55 p<0.02 
FPS improvement  ≥1 42% vs. 44% 
OR 1.10 (95% CI 1.02-1.20) 
p<0.05 
p<0.05 
Overall Good Attainment at 3 months 71% vs. 74%, 
OR 1.14 (95% CI 1.04 -1.25) 
p<0.05 
p<0.01 
Shift from Poorer to Good Attainment  46% vs. 51% 
OR 1.18  (95% CI 1.05-1.33) 
p<0.001 
p<0.01 
 
3 month attainment of the 9 individual processes 
 
HbA1c 5682 (91%) vs. 7608 (91%) ns 
Retinal status 5252 (85%) vs. 7149 (85%) ns 
Urine ACR 5138 (83%) vs. 6826 (82%) p<0.05 
Serum Creatinine 5708 (92%) vs. 7730 (92%) ns 
Foot status 4448 (72%) vs. 6157 (73%) p<0.02 
Smoking status 5006 (81%) vs. 6985 (83%) p<0.001 
Systolic Blood Pressure 5593 (90%) vs. 7769 (93%) p<0.001 
Serum Cholesterol 5580 (90%) vs. 7500 (90%) ns 
Body Mass Index 5068 (82%) vs. 7249 (87%) p<0.001 
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Fig. 5.4: The change in the Failed Process Score at 3 months compared to baseline in the 2 
groups either as crude data (top panel) or re categorised as described (bottom panel).  
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12 Months outcome comparing multiple mailings (Active) vs. single 
mailing (Control) Groups 
Failed Process Score 
The baseline FPS was not significantly different between groups, nor was there any 
significant difference in the distribution in FPS categories (Table 5.6).  
There were point differences for the 3 month FPS (mailing versus non mailed p=0.024) as 
previously reported, and also at 12 months (single mailed vs. multiple mailed p<0.06) 
although, in analysis of variance, whilst the FPS score varied significantly within subjects 
over time (F=997.9, p<0.001), the between group intervention of multiple mailing just failed 
to have a significant impact on FPS (F=3.459, p=0.06) despite time point significances (Table 
5.6, Fig 5.5).   
However, considering the baseline status, those with a good baseline FPS of ≤1 had similar 
attainment between groups at 12 months (ns) whilst those with a  poor baseline FPS of ≥2 
were more likely to achieve good attainment at  12 months in the mailed group (Final FPS 
≤1,  49.2% vs. 46.0%, χ2=6.09, p=0.014).  
Thus, when considering the target group, those with lesser activation and a baseline FPS of 
≥2, meaning the exclusion of those with a baseline FPS of ≤1, in analysis of variance there 
was significant between groups effect (F=4.369, p=0.037),  in the active group the 3 month 
(p<0.01) and 12 month (p=0.01) FPS was significantly better, and their likelihood of 
achieving the good attainment category (12 month FPS ≤1) with mailing was 1.15 (95% CI 
1.02 – 1.29, p=0.022).  
HbA1c, Systolic Blood pressure and Cholesterol 
We selected those who had both a baseline HbA1c measure and a repeat HbA1c at least 4 
months after the initial mailing date (n= 10015, mailed 5637, not mailed 4378).    
In the whole cohort HbA1c improved over the year (HbA1c% 7.8 ± 1.6 vs. 7.5 ± 1.6, 
p<0.001).   
The crude end year HbA1c was not significantly different between groups (multi mailed 7.5 
± 1.6 vs.  single mailed 7.6 ± 1.6, ns) but this masked an impact in sub groups.    
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Considering baseline HbA1c% categories as ≤7.5, 7.6-8.4 and ≥8.5, and adjusting for 
variables in univariate analysis (r2=0.39, F=126.9, p<0.001; age p<0.001, gender (ns), 
ethnicity (ns), IMD score (ns), type of diabetes (ns)), the impact of being multi mailed was 
significant (F= 6.2, p=0.013).    
The significant difference lay amongst those in the baseline HbA1c category ≤7.5 (mailed 
HbA1c% 6.7 ± 0.09 (mean ± SEM) vs. 7.1 ± 0.08, F=11.1, p<0.01) (Fig 5.6).   
Analysis of the change between final and initial HbA1c values by HbA1c category showed 
this to be a small but significant avoidance of deterioration of HbA1c levels in those multi 
mailed (HbA1c% category ≤7.5, delta HbA1c% 0.31 ± 0.7 vs. 0.02 ± 0.6, F=10.3, p<0.01) 
whereas the other 2 categories showed an improvement, most marked in HbA1c category 
≥8.5, which was unaffected by mailing.  
There were no discernable differences between groups for blood pressure or cholesterol. 
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Table 5.5 
Demographics and Clinical Parameters of final cohort at 12 months. 
Active= Received 3 mailings 
Control= Received 1 mailing. 
Demographics Mailing (Mean ± SD) P 
 Active = 8045 Control = 5911  
Age (Years) 63.9 ± 14.5 63.4 ± 14.4 NS 
Sex (Male) 54% 55% NS 
Ethnicity (White) 69% 70% NS 
Deprivation Score 35.2 ± 15.7 35.9 ± 16.6 0.013 
Type 2 Diabetes 94% 94% NS 
Duration of Diabetes 10.4 ± 8.4 10.5 ± 8.7 NS 
Smoking (Never smoked)  60% 58% 0.015 
    
Clinical Parameters    
BMI (kg/m2) 30.9 ± 6.3 31.1 ± 6.3 0.05 
BP(mm Hg) 135 ± 16 132 ± 16 <0.001 
HbA1C (DCCT- %) 
(IFCC- mmol/mol) 
7.8 ± 1.7 
61.5 ± 18.1 
7.8 ± 1.7 
61.6 ± 18.3 
NS 
NS 
Urine ACR (mg/mmol) 8.7 ± 34.6 8.9 ± 43.9 NS 
Creatinine (µmol/l) 88.3 ± 43.2 89.1 ± 46.4 NS 
Chol/HDL Ratio 3.8 ± 1.4 3.8 ± 1.4 NS 
Primary Risk 71% 69% <0.003 
Primary Risk Score (Framingham) 18.0 ± 7.5 17.8 ± 7.4 NS 
Retinopathy 58% 57% NS 
Foot Risk 57% 57% NS 
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Table 5.6 
Comparison of FPS Score (Total and Dichotomised) between Active group (received 3 
mailings) vs. Control group (Received 1 mailing) 
 
Failed Process Score (FPS) Groups P 
All 9 Processes Active 
n= 8045 
Control 
n=5911 
 
Baseline 1.70 ± 1.78 1.71 ± 1.80 0.631 
3 Months 1.20 ± 1.81 1.27 ± 1.84 0.024 
12 Months 1.65 ± 1.92 1.72 ± 1.94 0.057 
Dichotomised FPS (FPS ≥2) n= 3380 n=2499  
Baseline 3.35 ± 1.58 3.38 ± 1.60 0.508 
3 Months 2.14 ± 2.26 2.27 ± 2.29 0.027 
12 Months 2.25 ± 2.29 2.38 ± 2.28 0.034 
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Fig. 5.5:  Pattern of Mean FPS change at 3 points (1=baseline, 2= 3 months and 3= 12 
Months) between Active and Control Groups as Total FPS (Top Panel) and Dichotomised 
FPS (Bottom panel)  
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Fig. 5.6: The mean (top panel)  and delta (bottom panel) HbA1c outcomes at the end of 12 
months categorised by baseline HbA1c status in those receiving multiple versus single 
mailings. 
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Patient Survey Outcomes 
The 1000 surveyed people were not significantly different in any demographic or other 
characteristics compared to those not surveyed (n= 5282, Table 5.9).  Of the1000, 419 and 
581 did or did not respond to the questionnaire respectively. Their demographic and clinical 
details are also given in Table 5.9.  Non responders were younger and more likely to be of a 
non-white Caucasian background, but there was no significant difference in gender, their 
index of deprivation, or in type or duration of diabetes.  
The results of the evaluation of “My Diabetes, My Information, My Plan” from the 419 
respondents are presented in table 6 and a positive response was expressed to every 
question (Table 5.7).  
In non-responders, the FPS was significantly worse as was attainment in every single one of 
the 9 subsidiary processes (Table 5.8).  In those where outcomes were ascertainable who 
had process measures with the 15 month time frame, non-responders had a higher HbA1c, 
BMI, serum cholesterol and were more likely to be smokers but there were no significant 
differences in mean systolic blood pressure. The proportion of those with HbA1c >9%, a 
systolic blood pressure of >160 mmHg (borderline significance) and a serum cholesterol 
>6mmol/l was higher in non-responders. The 10 year primary CHD risk score was 
significantly worse in non-responders when adjusted for the 6 year mean age difference 
between the groups (Table 5.8, Figure 5.7).  This effect between groups was independent of 
age (F=22.2, p<0.001). Despite the separation amongst middle age bands, the effect was not 
statistically different between groups within separate age bands. Overall this meant that an 
estimated 27 additional cardiovascular events might occur over the following 10 years in the 
non-responding group with current primary CHD risk. There were no significant differences 
in the crude prevalence of established microvascular disease (eye, foot or renal) or 
established secondary macrovascular disease.  
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Table 5.7 
Patient Survey Outcomes 
The responses to a questionnaire relating to an individualised diabetes information booklet which were categorised in a 4 point scale as: Yes 
definitely; Yes, to some extent; No, not really; No, definitely not. 
 
Questions Reponses received 
(n=419 of 1000) 
Yes definitely or 
Yes to some extent (%) 
Did you understand the purpose of this document and what it is meant to be used for? 397 355 (85) 
Were the contents of the report easy to read and understand and do they make sense to you? 404 354 (85) 
Was the information useful? 414 368 (88) 
Did this information give you more knowledge about your diabetes? 410 321 (77) 
Did this information help you to understand your diabetes better? 406 302 (72) 
Would this information help you to improve your diabetes? 408 317 (76) 
Would this information help you make changes in your diabetes? 406 316 (76) 
Would this information help you feel more in charge or control of your diabetes? 412 316 (76) 
Would you take this information with you to your next diabetes appointment with a doctor or a nurse? 402 312 (74) 
Did you think this information will help in your next visit of diabetes review with a doctor or a nurse? 408 325 (78) 
Would you like to receive information like this in the future? 409 328 (78) 
How often would you like to have this report with this sort of information about your diabetes? 406 358 (85)*  
Overall, do you think it is a good idea for people with diabetes to have this sort of report? 413 377 (90) 
Overall, do you think people with diabetes will use this information to take better care of them? 414 365 (87) 
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Table 5.8 
The demographic and clinical parameters of those randomly selected to be surveyed (with p 
values comparing responders vs. non responders) and those not surveyed.  
 Not Surveyed Surveyed P value 
Demographics  Responders Non responders  
Number 5282 (%)(± SD) 419 (%)(± SD) 581 (%)(± SD)  
Age (years) 58.5 ± 10 62 ± 10 56 ± 12 P< 0.001 
Gender (male) 3012 (57) 246 (59) 318 (55) ns 
Ethnicity                                      Caucasian,  
Asian,  
AFC,  
Mixed 
Other or Unknown 
2868 (54) 
1329 (25) 
254 (5) 
58 (1) 
773 (15) 
249 (59) 
76 (18) 
18 (4) 
4 (1) 
72 (17) 
293 (50) 
175 (30) 
20 (3) 
9 (2) 
84 (15%) 
 
P<0.001 
IMD Score 35.5 ± 15.7 34.4 ± 15.8 36.3 ± 15.3 ns, 
(P=0.054) 
Type of diabetes (type 2) 4881 (92) 389 (93) 537 (92) ns 
Duration of Diabetes (years) 9.7 ± 7.9 9.8 ± 8.2 9.4 ± 7.6 ns 
Failed Processes   
Failed Process Score 1.3 ± 2.0 0.8 ± 1.1 1.7 ± 2.3 P< 0.001 
HbA1c 517 (10) 19 (5) 76 (13) P<0.001 
BP  405 (8) 13 (3) 63 (11) P<0.001 
BMI 644 (12) 31 (7) 97 (17) P<0.001 
Cholesterol 581 (11) 31 (7) 87 (15) P<0.001 
Smoking status 846 (16) 47 (11) 112 (19) P<0.001 
Retinal screen 832 (16) 33 (8) 120 (20) P<0.001 
ACR 969 (18) 53 (13) 159 (27) P<0.001 
Creatinine 453 (9) 15 (4) 77 (13) P<0.001 
Foot examination 1343 (25) 83 (20) 167 (29) P<0.01 
Outcomes  
HbA1C 7.7 ± 1.7 7.5 ± 1.4 8.0 ± 1.9 P<0.001 
BP Systolic  133 ± 15 133 ± 14 134 ± 16 ns 
BMI 31.5 ± 7.2 30.6 ± 6.4 32.0 ± 6.7 P<0.01 
Cholesterol 4.4 ± 1.1 4.3 ± 1.0 4.6 ± 1.2 P<0.001 
Vascular Risk (Secondary) 1009 (19) 94 (22) 107 (18) ns 
1010 year CHD risk  (numbers calculable)  
Age adjusted 10 10 year CHD risk 
(antilog)  
13.3 ± 7.2 
(661) 
10.7 ± 2.1 
12.4 ± 6.2 
(288) 
9.3 ± 1.8 
13.3 ± 7.2 (373) 
12.0 ± 1.8 ns,  P<0.001 
Current smoker 753 (14) 39   (9) 102 (18) P<0.001 
ACR 8.8 ± 33.8 7.5 ± 30.1 11.8 ± 44.4 ns 
Creatinine 85 ± 41 85 ± 34 84 ± 55 ns 
Retinal Risk      Vision Threatening 
Background 
None 
464 (10) 
1384 (31) 
2602 (59) 
36   (9) 
115 (30) 
235 (61) 
62   (13) 
137 (30) 
262 (57) 
ns 
 
Foot Risk                                   High 
Intermediate 
Low 
551 (14) 
1113 (28) 
2275 (58) 
56   (17) 
85   (25) 
195 (58) 
55   (13) 
110 (27) 
249 (60) 
 
ns 
HbA1c ≥ 9% 835 (16) 50 (12) 113 (19) P<0.001 
SBP ≥ 160 mmHg  240 (5) 18 (4) 40 (7) ns, 
(P=0.054) 
Cholesterol ≥ 6 280 (5) 12 (3) 39 (7) P<0.01 
Any 1182 (22) 75 (18) 168 (29) P<0.001 
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Fig. 5.7: The mean ± SEM % Framingham 10 year primary CHD risk score in those who did 
or did not respond to the questionnaire. 
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Chapter 6: Discussion and Conclusion 
No one would deny that giving good quality, reliable and comprehensive information to 
people with diabetes is not right and appropriate in principle, and there is evidence that 
they want it, expect it and value it (224-227), but is it of any demonstrable value to their 
diabetes care?  
In this large scale, single health economy, randomised controlled trial we have 
demonstrated that the provision of structured information regarding all core diabetes care 
processes, with due consideration to its purpose, design and utility, had an overall positive 
affect on the complete / near complete attainment of those key care processes.  
It should be noted that the intervention and the 3 month assessment occurred at a time 
when UK primary care teams put in maximal effort to achieve the completion of diabetes 
care processes for the end of financial year payment relating to the NHS primary care 
diabetes quality outcomes framework (QOF). It has been shown in multiple assessments 
that the introduction of QOF led to a significant improvement in the documentation and 
completion rates of care processes (61, 62). This QOF process would tend to mask any effect 
of the intervention, and the process was applicable to both groups.  Therefore, any benefit 
of the mailed booklet with a single intervention, demonstrated over a short observation 
period, exactly coinciding with the time that primary-health care providers were actively 
trying to complete their contractual obligation (QOF) and thus attain their financial 
payment, is a surprisingly positive outcome.  
On the face of it, the effect of multiple mailing had no significant impact on patient 
activation as measured by the accrual of key diabetes processes in the FPS score. Nor did it 
have any significant impact on the key clinical surrogate marker of risk, but this however 
should be considered in relationship to the potential to benefit, as well as the balance of the 
likely impact of patient activation versus the magnitude of service activation.  
Nevertheless, mean numerical attainments or benefits might be considered to be moderate, 
or even marginal. This is because of the overall attainments related to impacts on specific 
sub groups. If patient activation is driven by this booklet and if attainment of the process is a 
marker of their engagement, then it is to be expected that those with pre-existing very good 
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attainment (FPS 0 or 1), who are de-facto already active and engaged, might not be further 
positively influenced. This indeed turned out to be the case. Thus, the target for benefit are 
people with poor engagement in poorer FPS groups, and we show that even those with 
much poorer attainment (including FPS 5 or more) seemed to show a continuum of benefit. 
In the whole cohort, almost 60% were already in a high attainment position and thus could 
not further benefit. When considering those with poorer attainment,  the pattern of initial 
improvement was more marked, and they did not deteriorate to baseline, while in the 
active group  the impact of single then repeat mailing was positive and significant, so that at 
the end of 12 months they were 15% relatively more likely to be in the higher attainment 
category.  Thus the impact of single or multiple mailing may be seen to have achieved its 
objective of having a significant impact over and above that of maximal service activation, 
and to have separately benefited the intended target groups in lower attainment categories.   
There was an interesting variation in the nature of this benefit across the cohort. This can be 
understood from the perspective of any diabetes model of care, including ours, and it is 
linked to the notion of patient activation. In WICKED, the notion of care provision is 
governed to be user centric, but in an increasingly fragmented NHS, it is almost impossible 
to attain integration between multiple providers (89). Thus, the focus is to set clear 
standards for care provision to providers, to permit access to quality health care to all 
people with diabetes within our health economy (horizontal integration) and to identify 
individuals according to their specific needs and risks and move fragmented services to 
integrate around them accordingly (vertical integration) through clinical governance and 
performance management (228).  
Crucial to this is the fact that people with diabetes become the drivers of their own health 
care. It is conventionally felt that for people with diabetes to have a sufficiently expert 
understanding of their condition, they require training and education (160), but equally, 
they cannot be knowledgeable or seek learning if they have no information. People with 
diabetes bemoan the lack of specific information given to them about their diabetes by 
health-care professionals and organisations and there is evidence to show that such 
information is both valued and valuable (184). It is on this basis that the trial was designed 
to determine if information would lead to patient activation and enable them and empower 
 
146 
 
them to achieve the processes of diabetes care that health-care providers struggle to attain 
(28).  
We have previously shown that those with increasing process failure very rarely “default” 
from care (229). Some simply have not been captured by the provision (15%), some are 
informed dissenters who may have made a choice not to access provision (30%), but most 
are those who wish to access care but cannot because of physical or psychiatric comorbidity 
or are house bound and immobile, and are thus constrained from becoming active in their 
own care. The booklet might not therefore have been expected to overcome such barriers, 
but it did appear to do so. We also note that in those who became activated during this 
period of time, such activation was further enhanced by the receipt of the document, such 
that not only did their score improve, but so too did their attainment of the targeted good 
attainment (GA) category. What we can also say, in relationship to worsening FPS outcomes, 
is that no harm appears to have been caused by this intervention. Hence, for example, in 
those in poorer attainment categories who might be dissenting from care, they might have 
been further discouraged, or others may have been falsely reassured and become more 
blasé, but there is no evidence of this, and thus no evidence of harm. 
Whilst we have focused on the benefit to these measurable diabetes care-process 
outcomes, other outcomes might be excepted to improve, and we have shown, in previous 
pilot work, that the document was wanted, needed, valued and well evaluated by people 
with diabetes, but also that it had had a very positive effect on doctors in their relationship 
with the patient and the understanding of their care needs (230).  
Then impact of HbA1c can be similarly considered. Our a-priori expectation was that if any 
differential impact were to have occurred, it would have been in those with poorer baseline 
glycaemic control, but the opposite result is perhaps predictable.  As is well recognised, the 
focus of clinicians and services will be on poorly controlled patients (26), service inertia and 
delay is a crucial reason for poor attainment in such patients (216) and the propensity to 
improve is almost certainly dependent on service intervention through drug titration and, in 
many patients, escalation to injectable therapies (231). A patient in this category is unlikely 
to have been able to influence their own outcome over and above the impact of service 
interventions. However, in the better baseline HbA1c attainment cohort (HbA1c ≤7.5%), the 
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service would have been less focused on them as they were already at or below the UK 
HbA1c attainment target (6), there would have been no perception that drug therapies 
required modification, and patients would have been more likely to have been able to 
significantly modify their own already good attainment, perhaps by diet and life style 
interventions or by improved concordance. The group with multiple mailings essentially 
maintained their HbA1c whilst the group with single mailing deteriorated by 0.3 HbA1c%. 
This seems small, but roughly equates to size of effect of the addition of a second or third 
line oral hypoglycaemic agent in Type 2 diabetes (232). 
The small size of any magnitude of effect can be further considered in the light of known 
evidence. In a recent Lancet metanalysis, non-pharmacological interventions were 
extensively reviewed (88). They can be categorised into 3 categories of quality improvement 
strategies targeting health systems, healthcare providers and people with diabetes.   It was 
concluded in this review that patient focused and health system wide interventions are 
more likely to influence outcomes in low to intermediate HbA1C risk group. However those 
with high HbA1C get most benefit from strategies focusing healthcare providers. This can be 
interpreted in the context of service related clinical inertia, where a clinician dependent 
intervention will have more benefit both in pharmacological and non-pharmacological 
interventions. However, we must acknowledge the fact that all such interventions have only 
shown modest improvements in hard outcomes such as HbA1C, which has only shown a 
mean difference of 0.37 %. Data from UKPDS suggested that a 1% reduction in mean HbA1c 
results in 21% fewer deaths, 14% fewer myocardial infarctions, and a 37% decrease in 
microvascular complications at the population level (233). An HbA1C improvement of 0.3% 
by our intervention might translate to 7% fewer deaths, 5% fewer myocardial infarctions, 
and 12% fewer microvascular complications at the population level. 
It is evident from the patient satisfaction survey that people with diabetes wished to have 
their individualised information in a structured format that is easy to understand and found 
it beneficial in a number of domains.   
To the best of our knowledge the use of this booklet is the first example to demonstrate 
prospectively that an information tool (as an intervention) can be used to improve patient 
activation with its  use resulting in a significant improvement in the completion of diabetes 
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process measured in the Failed Process Score (234).  We demonstrate that non response to 
the survey, equating to potentially poorer patient activation, was not only significantly 
associated with a worse FPS as another marker of activation but also with adverse clinical 
risk, as reflected by HbA1c, BMI, Cholesterol, smoking and primary CHD risk. We did not use 
a validated patient activation measure tool (168), which was beyond the remit of our 
project, but we took FPS and a failure to respond to the survey as indirect measures of 
patient activation. We accept that these may be assumptions, but highlight the conundrum 
that formally measuring patient activation can only be undertaken in those that engage in 
care. The true potential bias is thus the erstwhile low response rate to the survey.  The 
response rates to health surveys average around 60% (235) when using maximal techniques 
(236), and in surveys with 1 reminder a response rate of 40% is typical (237) and we 
emphasise that the selected population was a random sample that did not differ 
significantly in any regard from the wider cohort which minimises any potential bias linked 
to non-response. In retrospect, we could have selected a smaller sample size backed up by 
multiple reminders to enhance our response rate to more typical rate of around 60%. 
A poor FPS score and low survey response may reflect poorer patient activation, which may 
in turn be associated with measurable increased risk. However, non-response does not 
mean that the information booklet is ineffective in modifying that risk. Our primary 
outcomes clearly demonstrated a greater impact on diabetes access and process measure 
outcomes in the poorer FPS categories. The potential therefore clearly exists, as a 
consequence of increased access and process attainment, that the adverse clinical profile 
may become modifiable through follow on service intervention. 
We have not carries any cost benefit analysis of this intervention as a part of this project. 
However, once a functional database is established, the cost of mail merge, printing and 
mailing via post came to an accrued cost of <£1 per patient. If we map this cost against hard 
outcomes of the interventions i.e. HbA1C improvement of 0.3%   and improved care process 
completion rate then it is highly likely that this intervention will prove cost effective. Further 
cost benefits can be extracted by targeting people with diabetes in high risk categories that 
will result in reduce mailings and hence less cost.  
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The limitations of the study are acknowledged to be the relatively small magnitude of 
change observed, the relatively short time frame to first assessment of mailed vs. non 
mailed group and the inability to assess longer term clinical outcomes within the time 
frame. It is possible that the observed benefit at 3 months could have been by chance or 
random finding but persistence of improvement at the end of 12 months has confirmed the 
benefits of intervention. The strengths of the study include its large size, minimal loss to 
follow up and cluster randomisation methodology used to provide robust evidence in this 
evidence deficient arena of diabetes care.   
In summary, in a large randomised controlled trial, we have demonstrated that the 
provision of structured diabetes-specific clinical information, through a specifically designed 
booklet, led to significant improvements in diabetes process outcomes with no evidence of 
harm. People with diabetes are able to understand their most important diabetes related 
information when it is presented to them in a simple but structured format.  The booklet is 
easy to generate, and is seemingly low tech, with the proviso that the enabling background 
complexities of data integration and quality assurance are at a very high and well governed 
standard. It should be easily reproducible in other health economies. It can be disseminated 
independent of health care professionals and systematically distributed across a whole 
population.   It provides people with diabetes with an opportunity to reflect on their own 
status and take action and it does facilitate their consultation with healthcare professionals 
(230).   It does promote patient activation even amongst those with a poorer baseline FPS 
scores (234).  Indeed, this greatest impact seemed to be amongst those with poorer prior 
attainment in which the booklet enhanced their activation as determined by their improved 
FPS score and their attainment of the best outcome category. This effect appears to be 
independent of all demographic factors and the baseline marker of patient activation. This 
study can be used in future as a pilot to navigate the fundamental principles of a model of 
user centric, data driven diabetes care delivery. The service activation limb of this model is 
subject to another project to produce valuable information and to help designing better co-
working strategies based on evidence that may facilitate adoption of the WICKED model as a 
widely accepted model of diabetes care delivery in the NHS. 
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Mr Mickey Mouse
1 Hollywood Blvd
Hollywood
Los Angeles
LA1 A12
Dear Mr Mouse DOB 1/1/1900; Hosp No. A123456;  NHS No.123 456 7891
My Diabetes, My Information, My Plan
We are writing to you on behalf of local NHS services delivering diabetes care in 
Wolverhampton.
This letter has important information about your diabetes.
Please use it to understand your diabetes and what you may need to do or to change 
in order improve your health.
You can also use it when you see your GP or practice nurse, the hospital diabetes 
service or other health professionals. Please feel free to ask them questions about 
things that concern you or that you don’t understand. You can work through this report 
with them. Use it to raise any concerns or questions you have. You and your health 
care team will find this helpful in making the best plan for your health care, a plan that 
will more suit your needs. 
That’s why this is called “My Diabetes, My Information, My Plan”.
On the following pages you will find:
•	 Guidance notes (back page). 
• “My Diabetes Information” - a report covering all of your diabetes results and 
examinations (page 2).
• “My Diabetes Plan” - a plan maker to help you to assess or judge your own 
diabetes care and make a plan of action if it’s needed (page 3).
If you do not have diabetes or you feel this letter should not have been sent to you, 
please kindly let us know by phoning on 01902 695629.
Wolverhampton Diabetes Care
14
Guidance Notes
My Diabetes Information Report
The report on page 2 has items of information about your diabetes.
Each item is a measure or test and has a description explaining what it is. It shows 
the latest result over last 15 months. Ideally they should be less than 12 months old. If 
a test hasn’t been done or is out of date, please get it done as soon as possible, You 
may not be getting the correct care or treatment if out of date information is used.
It then gives you the guidance based on your results so you can work out if the 
situation is “Good”, “Borderline” or “ Of concern”. You may already be aware of this 
and you may already be on the correct treatment plan. In any case, judge whether you 
understand what the result means and whether you need to do something about it. 
If you are still not clear about the result, or feel action is needed, see your GP team for 
advice - ask for a routine appointment (not urgent) with your GP surgery.
My Diabetes Plan
Having worked through your information in “My Information” and having come to your 
own view about each item of diabetes care, please look at “My Plan”.
Again there are a number of sections. Decide where you stand on each of them - mark 
down if it is “Good”, “Borderline” or “Of concern”.
Decide where you would like to be. For example - what level of diabetes glucose 
control or blood pressure control are you aiming for? Always think of what is best for 
you in your situation. Then think about what you might need to do to get there and try 
and make a plan. Use this plan to improve your diabetes care. Feel free to use it with 
your diabetes team to help them understand your worries and your needs.
You may have other items of concern - please make a list of them as needed. There is 
space for you to make further notes and comments if you wish.
Definitions
Good = the result is satisfactory and acceptable with no need to worry. Lower risk.
Borderline = should be better and adjustments need to be made. Medium risk
Of Concern = in definite need of improvement and further testing and must be kept 
under close review. Higher risk.
My Diabetes Information Report
Symbols: “<” means “less than” and “>” means “more than” 
The levels that are in keeping with “Good” or “Of concern” are shown
Measure or Result
(Good, Of concern)
Value Clinical 
Comment
What is it?
Weight 73.4 See BMI Measure of weight in kilograms
BMI
(<25, >30) 32 Of concern Weight in relation to height
Blood pressure
(<140, >160) 167 Of concern
Blood pressure
(top number).
Cholesterol 
or Chol to HDL ratio
(<4.5, >5.5)
5.6 Borderline
Blood test of cholesterol
or Cholesterol corrected for 
“good” HDL Cholesterol if 
known
Smoker 
(Non-smoker) No Good Question of smoking status
Blood vessel circulation 
risk
Primary / Secondary Primary Good
Circulation risk. 
Primary means no 
circulation illness. 
Secondary means 
heart, stroke, leg or foot 
circulation problems.
Primary Risk Score
(<15%, >30%) 24% Borderline
Calculation of blood vessel 
circulation risk over 10 
years.
Eye Exam No 
Changes Good
Test for diabetes changes 
at back of eye by 
photography.
ACR 
(< 3.5, >10) 15.7 Of concern
Urine protein test for 
early diabetes changes in 
kidneys.
Creatinine 
(<120, >150) 138 Of concern
Blood test of kidney 
function.
Foot exam Low risk Good Test for nerve or circulation damage.
HbA1c DCCT
(< 7.5%, >8.5%) 7.2 Good
Blood test of long term 
diabetes or “Sugar” control.
HbA1c IFCC
(< 58, >70) 55 Good
Same as above but using 
new units of measure (as 
above).
2 3
My Diabetes Plan
My opinion
Where do I stand?
Circle your status in each box
My Feelings
Where do I want to be?
My Plan
What steps should I 
take?
My Lifestyle 
(Diet, exercise, smoking) 
Good, Borderline, Of Concern
My BMI (Weight)
Good, Borderline, Of Concern
My Blood Pressure
Good, Borderline, Of Concern
My Cholesterol
Good, Borderline, Of Concern
My Circulation Risk
Low, Medium, High
My Eyes
Good, Borderline, Of Concern
My Kidneys
Good, Borderline, Of Concern
My Feet
Good, Borderline, Of Concern
My HbA1C (sugar control)
Good, Borderline, Of Concern
My Hypo Risk
(risk of low blood sugars)
Low, Medium, High
My Medication
Good, Borderline, Of Concern
My Diabetes Know how
Good, Borderline, Of Concern
My Well-being
Good, Borderline, Of Concern
Other:
Other:
My Comments:
MI 063814 12.05.14  
 
 
 
 
 
A questionnaire about the document 
“My Information, My Diabetes, My Plan” 
 
 
 
PLEASE HELP 
 
 
 
 
 
 
 
 
 
 
 
Dear PT NAME 
 
 
DOB Hosp NHS 
 
You recently received your “My Diabetes, My Information, My plan” document. We 
would like to know if it was helpful. 
It would help us to understand whether the report, its instructions and the information contained was clear and 
useful. 
 
Please take some time to answer all of the questions over leaf. 
 
 
Read each question and circle the answer the box that most represents your view. 
 
When you have finished, please send it back using the stamped addressed envelope provided. 
 
Many thanks for your help. 
 
         
 
Dr. B M Singh       Dr. Syed Gillani 
 
        GP and Clinical Research Fellow in Diabetes 
 
        New Cross Hospital Wolverhampton 
MI 063814 12.05.14  
CIRCLE JUST ONE ANSWER FOR EACH QUESTION 
 
 
Did you understand the purpose of this document and what it is meant to be used for? 
Yes definitely   Yes to some extent  No not really   No definitely not  
 
 
Were the contents of the report easy to read and understand and do they make sense to you? 
Yes definitely   Yes to some extent  No not really   No definitely not  
 
 
Was the information useful? 
Yes definitely   Yes to some extent  No not really   No definitely not  
 
 
Did this information give you more knowledge about your diabetes? 
Yes definitely   Yes to some extent  No not really   No definitely not  
 
 
Did his information help you to understand your diabetes better? 
Yes definitely   Yes to some extent  No not really   No definitely not  
 
 
Would this information help you to improve your diabetes? 
Yes definitely   Yes to some extent  No not really   No definitely not  
 
 
Would this information help you make changes in your diabetes? 
Yes definitely   Yes to some extent  No not really   No definitely not  
 
 
Would this information help you feel more in charge or control of your diabetes? 
Yes definitely   Yes to some extent  No not really   No definitely not  
 
 
Would you take this information with you to your next diabetes appointment with a doctor or a 
Nurse? 
Yes definitely   Yes to some extent  No not really   No definitely not  
 
 
Did you think this information will help in your next consultation with a doctor or a nurse? 
Yes definitely   Yes to some extent  No not really   No definitely not  
 
 
Would you like to receive information like this in the future? 
Yes definitely   Yes to some extent  No not really   No definitely not  
 
 
How often would you like to this sort of report with this sort of information about your diabetes? 
Once a year  twice a year  I don’t want to have this information  
 
 
Overall, do you think it is a good idea for people with diabetes to have this sort of report?  
Yes definitely   Yes to some extent  No not really   No definitely not  
 
 
Overall, do you think people with diabetes will use this information to take better care of 
themselves? 
Yes definitely   Yes to some extent  No not really   No definitely not  





A Research Ethics Committee established by the Health Research Authority 
 
 
 
NRES Committee North East - York 
Room 002 
TEDCO Business Centre 
Viking Business Park 
Rolling Mill Road 
Jarrow, Tyne & Wear 
NE32 3DT 
 
Telephone:  0191 4283545 
13 February 2013 
 
Dr Syed M R Gillani 
Academic Fellow Diabetes 
The Royal Wolverhampton NHS Trust 
Wolverhampton Diabetes Centre 
New Cross Hospital, Wednesfield Road 
Wolverhampton 
WV10 0QP 
 
Dear Dr Gillani 
 
Study title: The NHS Choice and Information Revolution - exploring 
the utilization of high quality clinical data governance 
processes to promote informed patient driven care in a 
locally integrated English diabetes health economy. 
REC reference: 13/NE/0052 
IRAS project ID: 117977 
 
Thank you for your email of 11th February 2013.  I can confirm the REC has received the 
documents listed below and that these comply with the approval conditions detailed in our letter 
dated 08 February 2013 
 
Documents received 
 
The documents received were as follows: 
Document    Version    Date    
Other: My Diabetes, My Information, My Plan       
 
Approved documents 
 
The final list of approved documentation for the study is therefore as follows: 
  
Document    Version    Date    
GP/Consultant Information Sheets  GP letter, V1     
Investigator CV  Dr Syed Gillani CV, January 2013     
Other: Baldev Singh CV       
A Research Ethics Committee established by the Health Research Authority 
 
 
Other: My Diabetes, My Information, My Plan       
Protocol  Project Proposal V1, January 2013     
REC application  3.4     
 
You should ensure that the sponsor has a copy of the final documentation for the study.  It is 
the sponsor's responsibility to ensure that the documentation is made available to R&D offices 
at all participating sites. 
 
13/NE/0052 Please quote this number on all correspondence 
 
Yours sincerely 
 
 
 
 
Hayley Jeffries 
Committee Co-ordinator 
 
E-mail: hayley.jeffries@nhs.net 
 
 
Copy to: Mrs Yvonne Hague, The Royal Wolverhamptom NHS Trust 
 
Mrs Lorraine Jacques, The Royal Wolverhampton NHS Trust 
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